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The eradication of pathogenic bacteria in cystic fibrosis (CF) lungs is often unsuccessful 
because of the poor permeability of the drug through the thick respiratory mucus barrier and 
biofilm. Nanoparticles are promising carriers due to their ability to cross these barriers and to 
deliver the loaded drug into the site of action. Nanoparticles exhibit a poor lung deposition; 
therefore, they need to be transformed into microparticles, which are suitable for dry powder 
inhalers and thus can be applied pulmonary. 
In this work, PLGA NPs loaded with Curcumin were produced using microfluidic technology. 
While using different factors during the manufacturing, their effect on the size and the 
encapsulation efficiency of the drug was evaluated. Also, the particles showed a fast 
permeability through the mucus barrier. Furthermore, a novel microparticulate matrix 
(composed of an antibiotic and N-acetylcysteine) was developed using a spray-drying 
technique in order to embed the NPs within it and to add even more functionality to the 
formulation. 
The aerodynamic properties of microparticles were tested using NGI. Then, their impact on 
the viscosity of mucus was tested. Additionally, a solid-state characterization and 
investigations regarding the physical stability of the obtained DPI formulations were 
performed. Finally, their effect against biofilm formation and inflammation was tested. 
Summarizing, the formulations represent a promising approach for the future treatment of 
























Oft misslingt die Eradikation pathogener Bakterien in Atemwegen von Mukoviszidose 
Patienten. Grund ist die schlechte Permeabilität des Arzneistoffes durch den pulmonalen 
Mukus und den Biofilm. Nanopartikel sind hierfür vielversprechende Trägersysteme, da sie 
diese Barrieren durchdringen und den geladenen Arzneistoff an den Wirkort bringen können. 
Aufgrund der geringen Deposition von Nanopartikeln in der Lunge ist die Umformulierung 
der Mikropartikel nötig, damit sie pulmonal appliziert werden können. 
In dieser Arbeit wurden durch Verwendung von Mikrofluidik Kurkumin beladene PLGA 
Nanopartikel hergestellt. Der Einfluss verschiedener Herstellungsfaktoren auf Partikelgröße 
und Verkapselungseffizienz wurde bewertet. Die Partikel zeigten eine rasche Permeation in 
den Mukus. Mittels Sprühtrocknung wurde eine neuartige Matrix (aus Antibiotikum und N-
Acetylcystein) entwickelt, die die Einbettung der Nanopartikel erlaubt und die Funktionalität 
der Formulierung weiter steigert. 
Die aerodynamischen Eigenschaften der Mikropartikel wurden mittels NGI untersucht und 
die Verflüssigung des Mukus wurde nach Anwendung gezeigt. Die Formulierungen für den 
Pulverinhalator wurden im festen Aggregatzustand charakterisiert und ihre physikalische 
Stabilität getestet. Schließlich wurde ihre biologische Wirkung (gegen Biofilme und 
Entzündungsreaktionen) untersucht. 
Die Formulierungen stellen einen vielversprechenden Ansatz für die künftige Behandlung 
von pulmonalen Infektionen bei Mukoviszidose dar. 




1.1  Cystic fibrosis 
 
Cystic fibrosis (CF) is the most typical severe chromosomal recessive disorder; it recorded 
among Caucasians with an incidence of one case per 2500 births [1, 2]. It is also very well 
known as multi-organ disease as it influences the lungs, small intestine, gall and pancreas. 
The most prominent reason behind this disease is a mutation in a single gene on 
chromosome number (7), followed by the formation of the translated protein called Cystic 
Fibrosis Transmembrane Conductance Regulator (CFTR) which works as a cAMP-
regulated chloride channel [1, 2]. Hence, the mutation in CFTR results in the misfolding or 
malfunction of proteins which fail to reach the apical cell membrane. Furthermore, altered 
CFTR causes unregulated chloride and subsequently Na+ transport which thus leads to 
improper water absorption in response to the net transport of NaCl [3, 4]. This improper 
content of water in lungs leads to dehydration of the airway surface liquid (ASL) which is 
giving rise to build-up viscous mucus which is as well triggers impaired mucociliary 
clearance (MCC) [3]. As a result, the cilia cannot beat efficiently in such drastic condition, 
resulting in the entrapment of bacteria in the viscous airway surface liquid (ASL) for a 
prolonged period of time. Such prolonged infections increase the risk of life-threatening 
lung infections and inflammation [3, 4]. Persistence of such condition may eventually 
initiate tissue damage as it is illustrated in the cycle of lung disease in (figure 1) [5]. It has 
been shown that CF patients have a higher risk of bacterial infections such as 
Haemophilus influenza and Staphylococcus aureus which always happen in an early stage 
of the disease [6]. Nevertheless, Pseudomonas aeruginosa (P. aeruginosa) is the major 
infective pathogen which influenced the lung of patients in CF and the treatment for P. 
aeruginosa infection is very difficult to be cured, due to the mucoid growth of the bacteria 
[6, 7]. The thick mucus and as well the chronic bacterial infection with well-protecting 
biofilm matrix is considered the main challenge for efficient therapy in CF lungs [2].  


































Nonetheless, a successful treatment for curing the CF diseases would rely on providing a 
gene therapy or CFTR correctors. Although research is still under investigation particularly, 
gene therapies are still far away from being available as a product on the market [8]. For 
CFTR correction, Ivacaftor (oral drug) is the only and first CFTR potentiator available on 
the market. Unfortunately, only 4% of patients who carry the specific mutations, which 
responsd to Ivacaftor treatment, can benefit from it [9]. Due to lacking gene therapies, the 
whole concept of the treatment mainly relays on symptomatic therapy in order to increase 
the life expectancy of the patient and improve their quality of life. In the last few years, an 
increase in the life expectancy of CF patients from 18 to 31 years was observed (1995-
2012) indicating the success of general treatment [2, 5, 9, 10]. Despite all these 
improvements in the treatment, eradication of pathogenic bacteria is still facing several 
challenges such as developing a resistance towards antibiotics after a long time of 
treatment. Therefore, improvements in the treatment of CF are still needed to ensure a 
better quality of life and prolong the life expectancy of the patients.  
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1.2  The strategy for the treatment of cystic fibrosis disease 
 
As it is illustrated in table 1, the concept of the treatment in CF disease is mainly based on 
symptomatic therapy such as using high doses of antibiotics to counter microorganism 
infections and manifestation of biofilms. For a sufficient treatment against bacteria, co-
therapy treatment such as a combination of orally antibiotics (P.O.) with intravenously (i.v.) 
or pulmonary (inhalation) applied antibiotics is more appropriate for evading the resistance 
of bacteria towards antibiotics [10]. Even though the systemic therapies afford a successful 
treatment, their sturdy adverse effects in gastrointestinal tracts like nausea, diarrhea, and 
vomiting are the main restraint for not being the first choice [11]. Therefore an alternative 
route of administration of antibiotics is needed. Taking antibiotics in the inhalation dosage 
form is more convincing, due to the requirement of fewer doses in comparing to the oral 
dose. Furthermore, according to the last guideline for treating CF disease, it is always 
recommended to take a mucolytic agent such as N-acetylcysteine (NAC) or other 
inhalation drugs like dornase alfa and saline prior to antibiotics dose [2, 12]. The aim of this 
combination therapy is to fluidize the abnormal viscous mucus by the mucolytic agents and 
it is also intended to aid the antibiotics to diffuse faster through the less viscous mucus and 
indirectly facilitate also mucociliary clearance [13]. Moreover, D-Mannitol (an osmotic 
material) has gained a great deal of attention within the scientific community, since it works 
as an osmotic agent within the respiratory organs [14]. The mechanism of action works by 
permitting the water to accumulate within the lung lumen resulting in decreasing the 
consistency of the thick mucus barrier [14].  
In addition, to slow the progression of airway inflammation in CF lung disease, a dose of 
corticosteroids and nonsteroidal anti-inflammatory drugs like Ibuprofen (NSAIDs) is highly 
recommended. Moreover, Ivacaftor as CFTR corrector drug can be used in CF patients, 
but only in case the patient can respond to the ivacaftor treatment [9]. At the final stage of 





















Promote airway clearance 
 Physical techniques (like physical therapy, high–frequency chest wall oscillation) 
 Pharmaceutical approaches (like Dornase alfa, hypertonic saline, albuterol) 
 Exercise 
Treat bacterial infection 
 Systemic antibiotics  






Replace damaged lungs 
 Lung transplantation 




1.3  Overcoming biological barriers using nanoparticles 
 
In the light of nanotechnology science, nanoparticles (NPs) are represented as an 
attractive drug delivery system because NPs have the potential to overcome the thick 
mucus and biofilm barrier in CF patients (Fig 2) [15].  
 
 
Fig. 2: Normal and CF airways. Source www.discovermagazine.com 
 
The advantages of using nano-carrier systems in CF are (1) permeation of drug through 
the thick mucus in CF, (2) aiding the drug for a better permeability through biofilm matrix, 
(3) protection of the drug from inactivation inside the mucus and biofilm, (4) offering a 
controlled and sustained drug release profile [15, 16]. The combination of these 
advantages can result in decreased toxicity and at the same time improved effectivity of the 
used drug as compared to traditional formulations. Generally, to enable the particles to 
move freely through mucus without being immobilized, NPs should be designed with 








For the development of muco-penetrating nanoparticles, understanding of the filtering 
mechanisms of particulates within the mucus barriers is indispensable. Normally, the 
filtering of particles through the mucus barriers can occur in two steps, biophysical (size 
filtering) or biochemical (interaction filtering) mechanism [18]. As it is very well known that 
the size of the mesh structure of mucus differs depending on the state of disease, for 
instance, in CF disease, the pores size is in range of 150 ± 50 nm. Thereby, submicron 
particles with a size less than 100 nm are needed for avoiding their immobilization within 
the pores, ensuring of delivering drugs and across the mucus barrier [15, 18]. Regarding 
the interaction filtering mechanism, several interactions (e.g. H-bond interaction, 
electrostatic interaction; hydrophobic interaction, etc.) could occur [18]. Avoiding such kind 
of interactions can be accomplished by engineering the surface chemistry of particulate 
(charge) because it plays a decisive role in determining the level of interaction of this 
particulate with biological barrier. After conducting comprehensive studies on the way of 
NPs-mucus interaction, it was shown that using neutral or slightly negatively particles such 
as PEG-PLGA NPs diffuse more easily without restriction through mucus barrier in 
comparison to positively charged particles such as chitosan NPs  [19, 20]. The positively 
charged chitosan NPs tend to interact mostly with the negatively charged mucins via 
electrostatically interactions; therefore Chitosan NPs are categorized as muco-adhesive 
particulates [21]. On the flip side, the neutral or slightly negatively charged particles are 
categorized as muco-penetrating particles due to that the particles are mostly repelled from 













For this reason, the neutral particles exhibit faster permeability to cross the thick mucus 
barrier in CF. As mentioned before, negatively charged NPs with a diameter of ~ 100 nm 
such as PLGA-PEG NPs, have freely diffused without being immobilized in the pores of the 
thick mucus barrier, in contrast to the behavior of NPs with a diameter ~500 nm which have 
been retained within the mucus pores without crossing the mucus barrier (Fig. 3) [22-24]. 
 
 
Fig. 3: Size filtering mechanism of particles through the network of mucus. 
 
Apart from facilitating the permeability of NPs, coating or shielding the surface of NPs 
would add benefit in term of enhancing the stability of the formulation and might be as well 
contribute to hinder hydrophobic interactions [25]. 
Bacterial biofilm is also considered as the main challenging barrier for NPs to penetrate. 
The bacterial biofilm is an extracellular matrix containing several components such as 
polysaccharides, proteins, lipids, and nucleic acids which enrich the biofilm with negative 
charges [26]. The same as in the thick mucus in CF, the size exclusion and electrostatic 
interactions take place as well in the bacterial biofilm [18]. NPs have shown a better 
penetration in bacterial biofilm as well as a higher local concentration in the biofilms, due to 
the fact that the drug is perpetually released inside the viscous-mucus and not at once 
before being penetrated into the mucus barrier [16, 27]. To conclude, advanced drug 
delivery systems such as nanoparticles represent an ideal transport and protection carrier 








1.4  Obstacles in delivering nanoparticles to the lungs 
 
The lungs are an appealing area for drug delivery (air-to-lung-delivery) as it provides high 
solute permeability for the drug, its large surface vicinity for absorption and its restricted 
proteolytic activity [28]. The functional structure of the lungs is divided into 2 regions. The 
airways area which is including trachea, bronchi, and bronchioles and the second region 
called the alveoli which are for gas exchange. The respiratory system consists mainly of 
the trachea which is dividing into two branches called bronchi and then the bronchi still 
continue to branch into minuscule bronchioles where finally, the terminal bronchi are 
finishing with what is called the alveolar sacs (Fig.4) [29, 30]. In CF disease, it's most ideal 
that inhaled particles will be deposited in bronchioles as it is normally the disease process 
conventionally begin there and then reach out toward the bronchi area [29]. 
 
Fig. 4: Anatomical structure of airways according to the ICRP (International Commission on 








For treating the lung, inhalation therapy has shown superiority compared to other routes of 
administration, for instance, oral in term of [32]: 
 Non-invasive route of administration. 
 Enhanced drug bioavailability. 
 Rapid onset of action.  
 The ability of drug to avoid the first pass effect due to the fact that the drug          
metabolizing enzymes has very low concentrations within the lungs than in the digestive 
system and also the liver [33]. 
 A higher local drug concentration in comparison to systemic application as the inhalable 
drug reaches directly into the lung epithelium. 
 Straightforward route of administration and very useful for the patient who needs to take 
the drug regularly or patient who has liver or kidney problem.  
 
In respiratory research, it is still not straightforward for applying nanoparticles (NPs) directly 
into the lungs because of the chance of being removed during the exhalation process. For 
developing a drug formulation being applicable by inhalation, some key factors should be 
taken into consideration like breathing pattern, airways geometry, humidity, and particles 
morphology (MMAD, particles size, and particles shape), as these factors have a profound 
influence on the particles’ deposition inside the lungs of the patient [29, 34, 35]. The 
researchers have reported that the ideal MMAD of the particles is 1-5 µm for sufficient 
pulmonary delivery [35]. After ensuring the particles deposition, the physio-chemical 
properties of drug molecules would have an influence on the absorption rate such as 
molecular weight and lipophilicity. When inhalable particles are applied into lungs, they can 
be subject to diverse kind of deposition mechanisms such as inertial impaction, 
gravitational sedimentation, interception, Brownian diffusion and electrostatic precipitation 
(Fig.5). The sizes, density and shape of particles are the main factor which impacts their 
deposition inside the lung. 
 
 














Fig. 5: Particle deposition mechanisms in the lung [36]. 
 
Impaction phenomena happen in the extra-thoracic airways exactly at the point where right 
angle curvature of the pharynx and at airway bifurcations. Once particles have an 
excessive amount of inertia because of their size or velocity and also the airstream is 
shifting in direction, it might cause that the particles will hit the airway wall instead of 
following the flow. Additionally, an increase in total cross-sectional area would lead to a 
profound decrease in the flow velocity while particles go into lungs, impaction occurs more 
often in upper airway rather than in the lower airway [29, 34, 35]. 
Gravitational sedimentation phenomena are more prominent in the lower part of an airway 
and also in the alveolar region, due to the fact that airstream velocity is lessened there. For 
the reason of the gravity phenomena, particles can settle down during holding breathing or 
slow breathing. The rate of sedimentation is almost 3 second of breath-holding which is 









For submicron inhalable particles, a random Brownian motion is a driving force for their 
deposition into the lungs and thereby the small particles will be the first and the fast one to 
move for reaching inside the lung [29, 34, 35]. 
 
Fig. 6: Total and regional deposition based on the ICRP (International Commission on Radiological 
Protection) deposition model [35]. 
 
Diffusion of particles happen when the particles are below 1µm, whilst particles with an 
aerodynamic diameter between 1-10 μm tend for sedimentation or impaction [29]. These 
findings are in agreement with deposition model from the ICRP (International Commission 
on Radiological Protection) (Fig 6) where the total deposition is represented in two peaks. 
The first peak in the lower nanometer range has represented the deposition of inhaled 
particles by diffusion. The second peak represents the particles with an aerodynamic 












1.5 Nebulization in comparison with dry powder inhalers and metered dose 
inhalers 
 
Despite the fact that nanoparticles can be applied via nebulization for inhalation purpose, 
the nebulization technique is suffering from some drawbacks such as microbiological 
contamination, particles aggregation and lower stability and required a specifics storage 
condition like a fridge [37]. From the viewpoint of patients, nebulization is a complex 
technique to be used because of its less portable and time-consuming due to device 
preparation, maintenance and cleaning which will increase the risk of microbiological 
contamination and poor reproducibility of the aerosolized droplet [37, 38]. Moreover, there 
is not always a possibility to nebulize or spray drying virtually any drug because of some 
issues with their chemical stability. To successfully deal with these issues, using 
nanoparticles as a carrier system for delivering a drug is a promising technology. Overall, 
for treating a pulmonary disease, formulating the drug as a dry powder inhaler DPI is more 
preferable in comparison to nebulization. The formulated drug as DPI has superior 
properties because of its easy usage, the ability to deliver a high dose of the drug 
compared with nebulization, no contamination risk and its more stable under the storage 

















1.6  Techniques of interest 
 
In the upcoming sub-chapter, selected preparations and analytical methods which have 
been used for the work in this thesis will be presented. 
1.6.1 Nanoparticles using nanoprecipitation method   
 
In this work, two of the most common methods to manufacture polymeric nanoparticles 
(PLGA NPs) were used, namely the conventional nanoprecipitation and the microfluidic 
nanoprecipitation technique. Generally, nanotechnology has gained a huge interest in the 
last decades, especially in the pharmaceutical field. The growing interest is related to their 
unique advantages in comparison to the preparation of drug in classic techniques [40]. The 
advantages of the nanoparticles are listed below: 
 A lower dose is required in comparison to the classic formulation of a drug  
 The power of reducing the unwanted side effect due to using of a small dose  
 Providing a protection for the drug from e.g. degradation  
 Enhancing the solubility of poorly soluble drugs  
 Offering the opportunity to control the release profile of drugs which would be 
helpful to avoid delivering of high dose   
 Allowing some drugs to have an alternative route of administration for example by 
solving the solubility issue 
Due to these unique advantages of NPs, enormous research studies were conducted for 
manufacturing different kinds of nanoparticles with a different method. Moreover, the 
influence of adjusting some factors during the manufacturing process of NP was studied, in 
order to evaluate the effect on the properties of NPs such as size. Among all of the 
manufacturing methods, nanoprecipitation (solvent displacement) is the most favourable 









The principle of nanoprecipitation relies on mixing two miscible solvents, from which one is 
a solvent containing a polymer and the other one a nonsolvent containing a stabilizer. 
Hence, the polymer solution (solvent) is gradually added into the nonsolvent solution. As a 
consequence, the polymer is precipitated and forms NPs [41, 42]. Although so many 
methods for manufacturing NPs were developed, their chances of being applicable in 
pharmaceutical industries are unrealistic. These limitations in their use are related to the 
lacking reproducibility (variation from batch to batch). Recently, microfluidic technologies 
were developed as a promising technique to solve this issue. The microfluidic technique is 
based on mixing two reagents under laminar flow condition in a very short time less than a 
minute. As a consequence of that, controllability of the NPs properties is achieved [43, 44]. 
Currently, microfluidic is pointed out as the most ideal method for being adopted in 




















1.6.2 Microparticles preparation for inhalation therapy  
 
Formulating drugs in an inhalation dosage form is still quite challenging. One of the most 
challenge points is to formulate the drug with appropriate sizes, to enable their deposition 
inside the lungs. For formulation an inhalation dosage form, there is a possibility to use 
different approaches like milling “Top-down” or “bottom-up” such as precipitation by 
supercritical fluids process (e.g. spray-drying and freeze-drying) [45]. In this work I will 
focus on the technique which was mainly used: spray drying. 
1.6.2.1 Spray drying  
 
Spray drying “bottom-up” technique is a drying process in which liquid or suspended 
formulations converts into solid dried formulations. Also, it is a well-known technique in 
pharmaceutics as well as in the food industry. The process of spray drying consists of three 
fundamental operations process, namely atomization, drying and separation. The feed 
solution containing active pharmaceutical ingredients and the excipients is atomized by a 
nozzle or vibrating mesh into very small droplets, then, those droplets expose their large 
surface immediately to a heated gas flow. Thereby, a rapid evaporation of the liquid inside 
the droplets occurs, resulting in a solid dry formulation. Afterward, the dried formulation is 
separated from the drying gas by a cyclone or electrostatic precipitator (Fig 7) [45, 46].   
The important factors in the spray-drying process are gas flow, spray gas flow, inlet and 
outlet temperature, feed rate, as well as the concentration and composition of the spraying 
liquid. Thereby, a little change in these factors would have an influence on the size of dried 
droplets, shape, and density, which will also influence their aerodynamic properties.  
In the normal case, the most of sprayed particles have a spherical shape, but it is also 
possible to have an irregular structure like raisin shape or hollow and this is depending on 










Fig. 7: Diagram of a spray dryer, Source: BÜCHI B-290 Manual. 
 
 
“Formulation is all about playing with the excipient, factors of the preparation 
method and choosing the right technology” 
 
Moreover, low-density particles are very well suited for pulmonary treatment. In general, 
spray-drying (SD) technique is an appropriate preparation method to formulate 
microparticles intended for pulmonary application [47]. 
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2. Aim of the work 
 
Recently, there is a new trend to formulate the antibiotics in inhalation dosage form for 
treating chronic pulmonary infections such as cystic fibrosis. Therefore, there is growing 
interest for using nanotechnology, to formulate inhalable particles by taking the advantage 
of this carrier. Principally, nanotechnology is playing a pivotal role as a smart technology to 
carry the drug. Thanks to NPs of the faced problems in developing drugs, like poor-
solubility and poor permeability to cross the thick mucus barrier, could be solved.  
The overall objective of this thesis was to develop a multifunctional formulation intended for 
pulmonary application. Ultimately, these multifunctional formulations have the ability to 
permeate through the challenging thick mucus barrier and deliver their payload into the 
lungs. 
This work is subdivided into the following 3 parts: 
I. Manufacturing of small-size polymeric nanoparticles (PLGA NPs) of less than 100 
nm using nanoprecipitation in a microfluidic system, and comparing the effect of 
different preparation techniques on the encapsulation efficiency of the loaded drug. 
II. Development of a multifunctional microparticle matrix in the form of dry powder for 
the purpose of inhalation. The matrix is composed out of different types of drugs, 
using a spray drying technique. Further, the inhaled formulation will be 
characterized. 
III. Embedding of the PLGA-NPs into a multifunctional microparticle matrix for 















The first aim focuses on the manufacturing of a small polymeric nanoparticle (PLGA NPs) 
of a size below ~100 nm, using a microfluidic technique. Further, we tested the influence of 
changing some factors during the preparation on the NPs’ size and their encapsulation 
efficiency of the loaded drug. Then, we studied the permeability of the NPs through the 
mucus barrier. Furthermore, the impact of using different approaches during preparation on 
the encapsulation efficiency of the loaded drug into the nanoparticles was evaluated. 
 
The second aim focuses on formulating a multifunctional microparticle matrix composed 
out of multiple drugs (mucolytic agent and antibiotics). The multifunctional microparticle 
was achieved based on the salification process. Then, the liquid formulation containing the 
mucolytic agent and antibiotics was formulated into a dry microparticle formulation using a 
spray dry technique. The resulted dry microparticle formulation showed a proper 
aerodynamic property and a quick disintegration behavior which is suitable for pulmonary 
application. The main goal was to take the benefit of a mucolytic agent, to fluidize the thick 
mucus in CF, therefore allowing the other drugs to penetrate through the mucus barrier 
without being entrapped within the pores of the mucus barrier.  
 
The third aim focuses on incorporating the PLGA NPs loaded with an anti-inflammatory 
drug into the multifunctional matrix (nano-embedded microparticles). Then, the influence of 
NPs on the aerodynamic properties was tested. Moreover, the stability of PLGA NPs within 
the multifunctional matrix of microparticles was evaluated.






Preparation of size-tunable PLGA 
nanoparticles by microfluidics intended 
for mucus penetration* 
 
* This chapter is prepared for publication as a journal article: 
Nashrawan Lababidi1, Valentin Sigal1, Konrad Schwarzkopf2, 


















3. Preparation of size-tunable PLGA nanoparticles by microfluidics 
intended for mucus penetration 
3.1  Abstract 
 
Great challenges still remain for drugs to penetrate biological barrier like mucus in cystic 
fibrosis and also for the treatment of bacteria residing in biofilms embedded in mucus. Drug 
carrier systems such as nanoparticles (NPs) need to have a proper surface chemistry and 
small sizes to ensure their permeability through those hydrogel-like systems. This holds also 
true for mucus in cystic fibrosis showing increased barrier properties. Exclusively, we have 
employed a microfluidic system to fabricate coated PLGA nanoparticles with muco-
penetrating stabilizer (Pluronic), with hydrodynamic sizes ranging from 40 nm up to 160 nm. 
The preparation based on the nanoprecipitation method was successfully performed using 
LabSmith microfluidic system. The size dependence was evaluated by varying different 
parameters during preparation, namely polymer concentration, stabilizer concentration, 
solvent nature, the width of the focus mixing channel, flow rate ratio and total flow rate. 
Furthermore, the influence of the length of the focus mixing channel on the size was 
evaluated in order to understand the nucleation-growth mechanism. Surprisingly, the 
channel length was revealed to have no effect on particle sizes. Finally, the permeability of 
muco-penetrating PLGA NPs through pulmonary human mucus was assessed; small NPs 
with sizes less than 100 nm showed a fast permeation. 
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3.2  Introduction 
 
In the last decades, application of nanotechnology has gained significant attention especially 
in the biomedical field for vaccine delivery [48, 49], in anticancer therapies [50, 51] as well as 
for gene delivery [52, 53]. Owing to the nanoparticles' unique physicochemical properties, a 
specific modification on the surface of nanoparticles could be designed to meet the needs of 
the desired application [54, 55]. This holds also true for protecting the drug carriers from 
being inactivated by avoiding the interaction with the non-cellular mucus [56]. Nanoparticles 
(NPs) have shown a tremendous effect in terms of facilitating the diffusion of drug through 
such biological barriers for e.g. thick mucus in cystic fibrosis [23, 57]. Notably, only particles 
with sizes below 200 nm seemed to permeate well through mucus without being entrapped 
by size filtering mechanisms [18, 23]. Furthermore, modifying the surface chemistry of NPs 
is beneficial for avoiding the interaction filtering mechanisms such as H-bond interaction and 
electrostatic interactions [58-60]. Moreover, nanoparticles as carrier system have the ability 
to protect the drug from inactivation, to reduce unwanted side effects and to enhance the 
efficacy of the active pharmaceutical ingredient (API) such as solubility and bioavailability [7]. 
Among a large number of polymers for the preparation of polymeric nanoparticles, poly 
(lactide-co-glycolide) (PLGA) as a very benign material is considered as a highly potent 
material for all routes of administration. Thus, PLGA NPs have been extensively studied in 
the pharmaceutical field, relying on PLGA's biodegradability and its FDA approval in some 
products [61, 62]. Besides that, PLGA has the ability to incorporate various active 
pharmaceutical ingredient (API), showing a high encapsulation efficiency for hydrophobic 
drugs and also contribute to control the release of the incorporated drug [63, 64]. Many 
different methods were designed to prepare PLGA NPs such as double emulsion and 










Among many other techniques, nanoprecipitation has been adopted very quickly to prepare 
submicron particles, because it’s a simple and straightforward technique, without any 
chemicals additives being involved and also does not require harsh formulation parameters 
like energy input, mechanical shear stress as induced e.g. by sonification [67, 68]. The 
mechanism of nanoprecipitation is based on the mixing of a solvent solution for the polymer 
(organic phase) with a non-solvent solution (aqueous phase). Thus, full miscibility initiates 
PLGA precipitation and spontaneous formation of nanoparticles [69]. Nonetheless, 
preparation of submicron NPs in a conventional “bench-top” nanoprecipitation method is still 
facing several critical challenges which restrict them from being adopted in a pharmaceutical 
industry such as lacking reproducibility [70, 71]. This problem holds especially true for NPs 
below 200 nm which are more preferable in order to penetrate faster through biological 
barriers. Although several methods for the preparation of NPs below 200 nm were shown, all 
these methods are still facing a major challenge such as poor reproducibility (batch to batch 
variations) which makes them undesirable techniques. These issues were mainly attributed 
to poor control of the mixing time. An improved control on mixing time can be achieved 
utilizing impinging jets or microfluidic systems, as they allow to control mixing time in 
millisecond instead of a minute [72, 73]. The group of Farokhzad has explored that mixing 
time plays the major role to fabricate monodisperse colloids with the desired size. This can 
be manipulated by adjusting the flow rate ratio of the organic phase to the aqueous phase 
and changing the channel width. As well, fast mixing (as in microfluidics) has shown a 
variety of advantageous over conventional methods (bench-top) on the physicochemical and 












LabSmith system (LabSmith, Inc, Livermore, USA) was implemented for manufacturing 
PLGA NPs using the nanoprecipitation method. This system offers stable conditions to 
produce monodisperse particles with small sizes. At the same time it offers the possibility to 
vary key parameters during preparation such as channel diameters and channel length [74]. 
For successful permeation of the particles through mucus, particles as small as possible are 
needed. Furthermore, the encapsulation of a lipophilic model drug (Curcumin, a nonsteroidal 
naturally anti-inflammatory drug) was assessed comparing different preparation approaches. 
The anti-inflammatory drug was selected as a potential drug for loading into PLGA NP which 
would be meaningful to be used in e.g. cystic fibrosis, to address strong and continuous 
inflammatory responses [75]. Particle diffusion-related sizes were characterized by dynamic 
light scattering (DLS) whereas, the morphology was visualized by scanning electron 
microscopy (SEM). Finally, the penetration of muco-penetrating PLGA NPs through 
Pulmonary human mucus was assessed utilizing confocal laser microscopy (CLSM). 
3.3  Materials and methods 
3.3.1 Materials 
 
Porcine mucin, Curcumin and acetonitrile (ACN) were purchased from Sigma-Aldrich 
(Chemie GmbH, Steinheim, Germany) and poly lactic-co-glycolic acid (PLGA) (Resomer RG 
503 H, 50:50 ratios, average Mw = 24.000–38.000 Da) was obtained from Evonik Industries 
(Darmstadt, Germany). Amphiphilic block copolymer Poloxamer (Pluronic F68) was a kind 
gift from BASF SE (Ludwigshafen, Germany). Pulmonary human mucus was collected by 
the endotracheal tube method after informed consent from patients (Winterberg hospital, 
Saarbrücken, Germany). AlexaFluor-WGA (wheat germ agglutinin) was purchased from 
(Invitrogen, Oregon, USA). All materials employed in the preparation of nanoparticles were 








3.3.2 Manufacturing of PLGA nanoparticles in a microfluidics system 
 
Microfluidic system was assembled using a cross-channel microreactor design, connected 
via glass capillaries (180µm ID and 300 OD, Labsmith, Livermore, USA). Monodispersed 
PLGA NPs coated with Pluronic (F68) on the surface were manufactured as illustrated in 
(Sketch 1). 
 
Sketch 1: Design of microfluidic system. 
 In brief, the stock solution of stabilizer containing Pluronic F68 (0.1%) was dissolved in 
water and injected into the side channels (B) of the microfluidic reactor using a syringe pump 
(Harvard Apparatus PHD 2000 Syringe, Holliston, USA). In parallel, the organic phase 
containing 3 mg of PLGA in 1ml acetonitrile (ACN) was pumped into the middle channel (A) 
using another syringe pump (Multi Programmable Syringe Pump, Sarasota, USA). The flow 
rate ratios (FRR) of the two phases were varied from (0.05 up 1). The two liquids were 
brought together in the mixing channel and the PLGA started to precipitate and form NPs. 
PLGA NPs sample was collected from the outlet of the channel. Then, PLGA NPs 
suspension was left overnight under stirring to evaporate the organic solvent. Finally, PLGA 
NPs suspension were washed twice using centrifugation (30 min at 10,000 g at 4°C) and 
redispersed with MilliQ water to get rid of excess stabilizer. The experiments were conducted 
under the same condition in triplicate for all formulations. 
 
 




3.3.3 Characterization of colloidal PLGA NPs 
3.3.3.1 Measurement of size distribution 
 
The colloidal properties of PLGA NPs such as size and size distribution (PDI) were 
measured utilizing a Zetasizer Nano ZS90 (Malvern Instruments, Worcestershire, UK). 
Briefly, nanoparticles were suspended in 10 mM NaCl solution in order to measure the zeta 
potential based on the electrophoretic mobility. All measurements were performed at least in 
triplicate under the same conditions. 
3.3.3.2 Morphology with scanning electron microscopy (SEM) 
 
The morphology of the PLGA NPs was visualized utilizing a scanning electron microscope 
(SEM) EVO HD 15 from Zeiss (Jena, Germany). 10µl of PLGA NP suspension was dropped 
on a silica wafer, and then it was left for overnight drying at ambient conditions. Next day 
prior to visualization, NPs were sputtered with a thin gold layer (~10 nm), utilizing a sputter 
coater Quorum Q150R ES (Quorum Technologies Ltd, East Grinstead, UK).  
 
3.3.4 In vitro assessment the interaction of NPs with mucin as a simple model  
 
Mucin (1%) was dissolved in water containing 1 % NaCl and it was left overnight under 
stirring at room temperature to form a kind of artificial mucus (AM). The sample was stored 
in the fridge (4°C) until usage. AM was incubated with the suspension of PLGA NPs 
stabilized with different types of Pluronic in 1:1 volume ratio at ambient conditions for pre-
defined time intervals. Afterwards, the nano-suspension was centrifuged at 5000 g for 10 
min to separate the NPs from mucin prior to analysis. As reference, PLGA NPs without 
stabilizer were measured. The properties of the NPs after incubation with AM were 
measured using DLS to determine whether; NPs size will be increased as a response to 









3.3.5 The permeability of tunable muco-penetrating PLGA-NPs through 
pulmonary human mucus 
 
The permeation of Rhodamine-B labelled PLGA NPs coated with 0.1% Pluronic (F68) was 
confirmed by 3D time laps imaging utilizing confocal laser scanning microscopy (CLSM), 
(LSM710, Zeiss, Jena, Germany). Each 40 µl of pulmonary human mucus without air 
bubbles was labelled with 1 µl of AlexaFluor-wheat germ agglutinin. Afterwards, the stained 
mucus was placed in an imaging chamber made by nail polish on a cover slip resulting in an 
equally thick mucus layer [76]. At time zero, PLGA NPs were added on the top of mucus, z-
stacks within the mucus sample were obtained at constant distance from the bottom of the 
slide. PLGA NPs permeability through mucus was tracked by the change of the fluorescence 
signal. This approach allowed us to study the size-dependent permeation of PLGA NP 
through pulmonary human mucus. One day before the experiments, frozen native pulmonary 
human mucus samples were left to thaw in the fridge at 4 °C. Rhodamine-B labelled PLGA 
NPs of 60, 140 and 400 nm size were dispersed in MQ water at 0.1% w/v. 5 μl of the nano-
suspension was added on top of the mucus. Then, the time-dependent vertical penetration 
was observed by a 40×/1.1 objective at 37 °C utilizing humidified and temperature-controlled 
air in an incubation chamber (Zeiss, Jena, Germany) in order to avoid drying. The labelled 
pulmonary mucus was detected with ex = 488 nm and a detection between 467−554 nm. 
PLGA NPs were excited at ex = 561 nm and the signal were collected between 624−707 
nm. The permeability of NPs within mucus was assessed from 0 min up to 1 h after their 
application. All experiments were accomplished in triplicate. 
3.3.6 Evaluation of drug encapsulation efficiency using different NP preparation 
approaches 
 
To evaluate the encapsulation efficiency of Curcumin (EE-Cur) into PLGA NPs, the influence 
of using different technique was investigated. The EE-Cur after adding the organic phase 
into the aqueous phase by hand, using a syringe pump or using the microfluidic system was 
compared. In brief, (9:1) ratio of PLGA to Curcumin with a final concentration of 3 mg/ml was 
dissolved in 1ml of acetonitrile (ACN).  
 




Then, the organic phase was precipitated in an aqueous phase containing 0.1% Pluronic 
F68 as stabilizer. First, to prepare a conventional nanoprecipitation, a plastic syringe was 
used to inject the organic phase containing (PLGA-Curcumin)-mixture into the aqueous 
phase by hand. In parallel to this, the second approach was carried out using a syringe 
pump (Harvard Apparatus PHD 2000 Syringe, Holliston, USA) with a flow rate setting of 
0.1mL/min, while in the third approach, an organic phase flow of 20 µL/min and an aqueous 
phase flow of 200 µL/min were used in an microfluidic setup. The resulting flow rate ratio of 
0.1 was used as a standard for NP preparation. All experiments were carried out at least in 
triplicate. 
3.3.7 Determination of the encapsulation efficiency of curcumin 
 
For analysing the encapsulation efficiency of Curcumin (EE-Cur), 1 – 3 mg of the prepared 
nanoparticles (PLGA NPs) was dissolved in 2 ml acetonitrile. 200 µl of each solution was 
then transferred to a solvent resistant plate reader plate. The plate was placed in a Tecan 
plate reader (Tecan, Männedorf, Switzerland) and analysed using an excitation wavelength 
of 460 nm and an emission wavelength of 515 nm. A calibration curve for curcumin was 
prepared using acetonitrile (ACN) as solvent. Using the calibration curve, the amount of 
curcumin inside the sample solution was determined as [Drug encapsulated]. The stock 
solution for NP preparation contained in 10 mL acetonitrile 0.1 mg of curcumin for each 0.9 
mg of PLGA [Drug used]. With this and the analysed amount of curcumin in the sample 
solution, the encapsulation efficiency (EE) was determined using following formula:  












3.4  Results and discussion 
3.4.1 Influence of different parameters on the size of NPs  
 
Smaller nanoparticles (NPs) are proven to have a better diffusion through mucus, owing to 
their smaller size, which helps them to avoid the size filtration mechanism [23]. Furthermore, 
the surface chemistry of NPs plays a crucial role in facilitating their penetration through 
mucus [56]. In this context, we have used microfluidics to produce tunable sizes of poly 
(lactic-co-glycolic acid) (PLGA) NP coated with muco-penetrating stabilizer (F68). To gain 
more insight about the factors influencing nanoparticle sizes, various parameters such as 
flow rate ratio, PLGA concentration, nature of the solvent, diameter of the mixing channel 
and stabilizer concentration were tested. Furthermore, as our system allow us to cut different 
lengths of the mixing channel, the impact of the length of the mixing channel on the 
nucleation-growth mechanism of the nanoprecipitation was evaluated.  
 
3.4.2 Effect of flow ratio and total flow speed 
 
Flow rate ratio was calculated as low rate ratio= (flow of organic phase)/ (flow of a queous 
phase). We have varied the flow rate ratio (FRR) of the organic phase to the aqueous phase 
from (0.05-1) and the flow speed of the aqueous phase was varied from 10µl to 100µl while 
adapting the organic phase volume accordingly. At a flow rate ratio of 0.05, a substantial 
reduction on the NPs size from 160 nm to 60 nm with narrow size distribution (PDI) below 
0.05 was obtained (Fig. 1). The reduction in NPs size is attributed to the rapid and efficient 
mixing process as it was demonstrated in the literature [73]. Further, Ostwald ripening 
phenomena could be avoided at fast mixing times [77]. Additionally, it was observed that an 
increase in FRR above 0.2 (by adjusting only the organic phase flow rate) bigger NPs were 
obtained. 
 
Preparation of size-tunable PLGA nanoparticles by microfluidics 
32 
 

































Fig. 1: Effect of flow rate ratio and total volume of the aqueous phase on NPs size. 
This implies that an increase in the width of the focus point of the organic phase occurred as 
a result of the higher FRR as illustrated in sketch 3 [78]. For this reason, a longer time was 
required for the diffusive material to be mixed. Another scenario would be that an increase in 
NPs size at higher FRR is related to the use of larger amounts of solvent causing swelling of 
the NPs as proposed by Wang et al. [79]. Afterward, the next step was to test the influence 
of increasing the flow speed of the aqueous phase on the size of NPs. Therefore we have 
varied the aqueous phase flow from 10-100 µl/min while keeping the flow of the organic 
phase constant at 10µl/min. It was observed, an increase in the flow speed of the aqueous 
phase from 10 µl/min - 100 µl/min has led to a reduction in the mean diameter of the NPs 










Sketch 2: Illustration the impact of increasing the flow ratio on the mixing pattern. 
This evidence points to the fact that most likely the polymer concentration decreases by 
increasing the aqueous phase flow rate (a large volume of the aqueous phase is available), 
thus small NPs were obtained. Another reason could be that the rate of the NPs to grow got 
decreased as well [80, 81]. Markedly, the tendency of the NPs for aggregation decreased at 
a higher flow aqueous phase due to the usage of the large volume of water which prevents 
particle encounter. Moreover, the particles are easier to redisperse and more stable within 
aqueous suspension. 
3.4.3 Effect of polymer concentration 
 
Nanoprecipitation mechanism is predicted to be primarily ruled by the Marangoni effect 
where the concentration gradient and the concentration of the polymer play a role in 
influencing the colloidal properties [69]. For this purpose, the influence of polymer 
concentration (PLGA) on mean diameter of NPs was tested. 
 




It can be observed by varying the polymer concentration (PLGA) from 1 mg up to 10 mg that, 
a higher concentration of PLGA is related to an increase in mean particle size from 60 nm up 









Fig. 2: Effect of PLGA concentration on NPs size. 
This influence is most likely coming from increasing the viscosity of the organic phase which 
led to impeding the diffusivity of the organic phase in the aqueous phase, subsequently, a 
longer mixing time resulted. Also, it appears that a large number of nuclei is formed and the 
high concentration of polymer per unit volume promotes particle growth, therefore bigger 
particles were obtained [80]. Notably, using higher concentrations of PLGA than 10 mg 
resulted in clogging of the mixing channel because of agglomeration. For concentrations less 
than 1 mg we were not able to produce monodisperse PLGA NPs; several peaks ranging 
from 20 nm up to 100 nm were observed in DLS. As indication of the lacking monodispersity 
a PDI > 0.7 can be considered [81]. In literature, the formation of micelles from the stabilizer 
was discussed as potential reason for the very small particles [79].  
 





































3.4.4 Effect of the diameter of the focus channel 
 
Besides the flow rate, flow rate ratio and polymer concentration, another important factor is 
the channel geometry which also has an impact on NP sizes. This holds true especially for 
the width of the focus channel in which the formation of NPs take place. Literature has 
demonstrated that the key parameter to modulate NPs properties is the mixing time (τ^mix). 
The mixing time depends on the geometry as described by [73]. 
 
Where D is diffusivity of the used solvent, wf is the width of the focus channel, w is the width 
of the other channels, and FRR is the flow rate ratio of the organic phase to the aqueous 
phase. According to this equation modulating the width of the focus channel wf will modulate 
the flow rate of the organic phase to the aqueous phase. As our microfluidic system (Lab 
smith, Livermore, USA) has an unparalleled trait of the possibility to choose different 
diameters for the focus channels from 20 µm up to 300 µm, we have elucidated the influence 
of the channel width on the colloidal particles. In Fig. 3 can be seen that NPs size was 
reduce from 130 to 70 nm as a result of modulating the width of the mixing channel from 280 


















Fig. 3: Effect of diameter of focusing channel on NPs size. 
Due to the reduction of the channel diameter the mixing time was minimized at flow rate ratio 
(FRR = 0.05) from 2.19 to 0.27 ms. Additionally, a focus channel of 50 µm was tested but 
unfortunately it resulted in a multimodal size distribution of NPs which is most likely due to a 
non-stable flow pattern (turbulent flow instead of laminar flow). 
3.4.5 Effect of stabilizer concentration  
 
Also, to aid the NPs to permeate successfully through the mucus without being trapped, 
coating the PLGA NPs with a muco-inert stabilizer must be taken into consideration. Using 
the right stabilizing molecules would reduce the interaction with mucus and it would also at 
the same time foster stability of the colloidal system, minimizing agglomeration of NPs and 
nucleation growth [77]. To gain more insight about the influence of the stabilizer on the 
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It has a good safely profile [82] and was proven to be a muco-inert material [83]. Using 
Pluronic (F68 0.1%) as stabilizer, has shown a slight increase in NPs size from 70 nm to 90 
nm (Fig. 4). 

































Fig. 4: Effect of stabilizer concentration on NPs size. 
 
Our observation is consistent with results shown from Panagiotopoulos group indicating that 
the stabilizer has nearly no impact on the mean diameter of NPs [84]. The slight effects are 
in accordance with the expectation where adding stabilizer is thought to increase the 
viscosity of the aqueous phase and thus prolonged the mixing time. The small sizes of 
particles at low concentrations of Pluronic might be due to the dominating effect of the 
surface tension over the change in viscosity [85]. For low concentrations of Pluronic the 
viscosity might not be strong enough to play a crucial role whereas the surface stabilization 
is already occurring and influencing the growth of nuclei. These results were in accordance 
with results from the conventional methods (data not shown). 
 
 




3.4.6 Effect of solvent nature and solvent mixture 
 
The solubility of drugs fundamentally relies on the solvent. Therefore, assessing the 
influence of the nature of solvent on the colloidal properties of our drug carrier would be 
meaningful. Different solvents were used to elaborate their impact on NP size namely, 
DMSO, acetonitrile and acetone. We can see that there is no correlation between the 







But the Hildebrand solubility parameter correlates with the formation of small NPs (table 1) 
[86]. When DMSO was used as solvent, the size of NP was minimized from 120 nm to 40 
nm in comparison to acetone and ACN as can be seen in Fig. 5. This data underlines that 
the nature of the organic phase plays a decisive role controlling the diffusion of the organic 
phase to the aqueous phase which induces as well a change in the mixing time [87, 88]. 
 
 
Table 1: Physicochemical properties of the used solvents 











      
Acetonitrile 41.05 0.786 52.23 33225 24.28 
DMSO 78.13 1.1 71.03 52900 26.65 
Water 18.01 1 18.01 44000 48.03 
Acetone 58.08 0.784 74.08 31300 19.74 
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Fig. 5: Effect of solvent nature on NPs size. 
 
3.4.7 Effect of the length of the focus mixing channel 
 
Attempts have been made to explain the mechanisms of nanoprecipitation in order to have a 
better control over the kinetics of the colloid formation. To the best of our knowledge, no 
comprehensive study presented relevant experimental evidence enabling more insight into 
the nanoprecipitation mechanism. Our microfluidic system has a unique feature allowing us 
to select different lengths of the mixing channel. The impact of the length of the mixing 


























Fig. 6: Effect of length of the focusing mixing channel on NPs size. 
 
Fig. 6 displays that the length of the mixing channel has no impact on particles size. It can 
be seen at (0.05 flow rate ratio) that for all channel lengths the NPs size was 50-60 nm. Also 
for other flow rate ratios no influence of the channel length could be observed (Fig. 6). 
According to literature, nanoprecipitation is more linked to nucleation and growth which 
consist of three stages: nucleation, growth, and aggregation as illustrated in (sketch 2). 
Based on the theoretical description of the mechanism, the particle formation is dependent 
on the time available for growth and agglomeration. Aggregation is assumed to happen after 
the initial formation and it is assumed to depend on the length of the mixing channel [36]. 
Therefore, adjusting the length of the mixing channel so that its length does only allow nuclei 
formation should, allow to avoid the growth of NPs, ensuring that only the nuclei (small NPs) 
would be collected. Overall, separation of the three stages could be meaningful to 
understand their respective influence on the colloidal size. We can conclude that on a length 
scale of > 1cm the process is completed. 
 
 

































Sketch 3: Illustration of nucleation and growth mechanism of nanoprecipitation along the focus mixing 
channel in microfluidic system. 
3.4.8  Encapsulation of curcumin into PLGA NPs using different techniques 
 
Finally, after evaluating the parameters which are relevant to have an influence on the 
colloidal properties, incorporation of drug into the nanocarriers was addressed. The goal was 
to compare the encapsulation efficiency of curcumin into PLGA NPs while using different 
approaches (microfluidics, injected by hand or using a syringe pump). As can be seen from 
Fig. 7, loading the PLGA NP using microfluidics resulted in particle increase from 70 nm up 
100 nm in comparison to unloaded PLGA. In contrast, loading the PLGA NPs using injection 
by hand or using a syringe pump, exhibited in a larger increase in size up to 145 nm. Thus, 
microfluidic is an optimal method for producing small, loaded nanoparticles with a good 
reproducibility and small variability. 
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Fig. 7: Comparison of the size of NPs after encapsulation using different approach. 
 
Fig. 8: Encapsulation efficiency of curcumin using different approaches. 
This is associated with the ability of microfluidics to mix solutions under laminar flow 
conditions ensuring controlled precipitation and short mixing times. Moreover, the 
microfluidic approach revealed a higher encapsulation of the lipophilic curcumin into PLGA. 
Using microfluidics 67.15% of the drug was encapsulated while the average encapsulation 
was around ~55% using the conventional approach with a syringe pump (Fig. 8). 
 
 




Finally, the encapsulation efficiency of curcumin was only ~12% for NPs prepared by hand 
injection, due to lacking laminar flow conditions. This was in accordance with previous 
reports on drug encapsulation [73]. Overall, it was shown that microfluidics offer a reliable 
way for encapsulation without much variability in size (small standard deviation) and 
succeeded in reaching higher encapsulation efficiencies for curcumin. 
3.4.9 Nanoparticles’ interaction with mucin  
 
 
Stability of NP within biological fluids is an essential factor with respect to aggregation and 
potential biological effects [89]. This holds especially true for the interaction of the particles 
with mucus. To estimate this, mucin as a simple model was chosen for assessing the 
interaction of surfactant coated PLGA NP with mucin in comparison to surfactant-free PLGA 
NPs [83, 84]. Fig. 9 indicates that PLGA NP stabilized with Pluronic F68 or Pluronic 10500 











Fig. 9: Nanoparticles’ without surfactant and stabilized with different types of Pluronic and their 
interaction with mucin 
This is reflected by the absence of any size change, indicating that the stabilizer shielded NP 
from adsorption or bridging. Contrarily, surfactant-free PLGA NPs and other types of 
Pluronic (F127, 9400, 6200, 3100 and 6400) have directly shown aggregation (from t = 0 min 
on), connected to an increase in the mean size up to 400 nm. A considerable shift in PDI 
from 0.026 up to 0.3 was also noticed. Thus as expected, the coating of the particles is for 
such an application indispensable. The increase in size and the broad size distribution is 
related to the interaction of the hydrophobic polymer with mucins which has led for 
agglomeration, hampering the ability of the particles to serve as efficient drug delivery 
system. 
3.4.10  Permeability of NPs through pulmonary human mucus 
 
Besides specific surface chemistry to avoid the interaction with mucins, manufacturing NPs 
smaller than the pore size of mucus should be beneficial to avoid size filtering mechanism 
and thus facilitated their penetration through biological barriers [23, 52]. A CLSM-based set 
up was used to study the penetration of NPs through pulmonary human mucus [57]. 
Different sized PLGA NPs (60 nm, 120 nm, 400 nm) were synthesized using microfluidics 
(also labelled with rhodamine B). NPs in aqueous suspension were added on top of a thin 
layer of human pulmonary mucus.  




Then, the penetration kinetics was analysed by scanning a defined volume at a fixed 
distance from the objective at different time points. As illustrated in Fig. 10, stabilizer-coated 








Fig.10: Confocal laser scanning microscopy study of the penetration of 60,120 and 400 nm red-
fluorescent coated PLGA NPs with Pluronic F68 through 40 µm of pulmonary human mucus at 
predetermined time interval. Mucus was stained with wheat germ agglutinin (Green fluorescent). 
Scale bar = 20 μm 
 
Penetration was observed up to 1h after the application. In contrast, 120 nm PLGA NP 
reached the detection volume after 30 min, whereas, 400 nm PLGA NPs were not observed 
in the respective volume, as an indication of no or very slow penetration. The observed 
behaviour can be attributed to the different sizes of the particles as all particles were coated 
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3.5  Conclusion 
 
The ability of microfluidics to precisely mix reagents at short mixing times under laminar flow 
conditions, has allowed to generate monodisperse PLGA NPs with tunable sizes. After 
varying different factors during the preparation, the results showed that the most dominating 
influence on the NPs size was governed by controlling the mixing time. Furthermore, we 
could show that the formation of particles is not influenced by a particle growth mechanism 
due to the diffusion in the mixing channel for a certain time (as the length of the channel has 
no impact). In addition, small particles produced this way were perfectly suited to diffuse 
through mucus as a biological barrier without being immobilized. NPs around 60 nm have 
shown an improved penetration through pulmonary human mucus. In contrast, NPs of 400 
nm were trapped in mucus as it was expected due to the size filtering interaction. 
This well controllable preparation of small particles using microfluidic in combination with a 
specific muco-inert surface chemistry led to a promising drug delivery system which showed 
enhanced mucus penetration. Moreover, a higher encapsulation efficiency of curcumin ~ 
67.15% was obtained while using microfluidic in comparison to conventional 
nanoprecipitation methods. 
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4. Spray-drying for generation of an inhalable, multifunctional matrix 
for the treatment of biofilms as formed in cystic fibrosis 
4.1  Abstract 
 
Cystic fibrosis (CF) a serious lung disease is commonly susceptible to Pseudomonas 
aeruginosa colonization and this pathogenic bacterium is hard to be treated under the 
respective circumstances. The thick mucus in CF together with biofilm formation is the 
main reason for limiting the permeability of drugs for reaching their site of action causing of 
failure in the treatment of the bacterial infection. Beside the treatment with antibiotics, N-
acetylcysteine to fluidize mucus is always recommended as it allows for facilitated 
coughing. Although several formulations have been developed for being used as inhalation 
therapy in cystic fibrosis disease, still there is no comprehensive study on the role of 
combining antibiotics with N-acetylcysteine (NAC) in one formulation as multifunctional 
formulation (DPI). Using such a multifunctional formulation might contribute to ameliorate 
the treatment. In this work, we developed an innovative pulmonary dry powder formulation 
based on electrostatic interactions between NAC and antibiotics. NAC and different classes 
of antibiotics were prosperously spray-dried without using any organic solvent. The 
obtained mass median aerodynamic diameters were in the range for inhalation (< 5.0 µm). 
This approach allows potentially incorporating nanoparticles which will result in adding 
more functionality to the formulation. The multifunctional microparticles have shown 
synergistic effects against bacteria in biofilm assays due to NAC’s property of reducing 
viscosity allowing for a better way to reach the bacterial targets in the mucus and biofilm. 
The combination of antibiotics to treat bacterial infections and NAC to facilitate diffusion of 
drugs and coughing as a convenient treatment option might also enhance treatment 









4.2  Introduction  
 
Cystic fibrosis (CF) is a congenital lethal chronic disease in which thick and sticky mucus is 
secreted in different body organs such as the pancreatic duct, intestine, and lungs [90]. 
This abnormal thickness of the mucus causes problems like intestinal blockages and a 
reduced clearance of the airways. Further, bacterial infections come along with the disease 
and cause severe problems, for instance, the infection by Pseudomonas aeruginosa that 
colonizes into a resistant biofilm in the lung in the later stages of the disease. According to 
recent statistics, approximately 70,000 to 100,000 children and adults around the world 
suffer from CF [91]. 
The strategies of the treatment in CF partly rely on the application of inhaled antibiotics in 
high doses using nebulizers for the treatment of early infections and inhibition of biofilm 
formation as monotherapy or in addition to oral/IV antibiotics as “multiple therapy” [13]. 
Meanwhile, the guidelines related to treatment in CF, recommend taking a mucolytic agent 
to fluidize the mucus and osmotic material like Mannitol to preserve the hydration of the 
airway [92]. This allows the antibiotics to diffuse into mucus and biofilms to reach the 
pathogenic bacteria. Overall, the key advantage of inhalation approaches of antibiotics is to 
reduce systemic side-effects by avoiding their systemic circulation [93]. Currently, only 
(Tobi®, Novartis AG, Switzerland), aztreonam (Cayston®; Gilead Sciences, USA), and 
colistimethate sodium (Colomycin®, Promixin®) are available on the market for application 
via nebulization [94-96]. Nebulization technique is still suffering from several drawbacks 
such as the majority of nebulizers could be a source of bacterial infection due to the 
contamination of equipment, losing drug during aerosolization process, long time of 
administration is required and a reduced performance of the machine over time [97-101]. 
Some sort of nebulizers would also need a longer time to complete aerosolization resulting 
in non-optimal aerosols [102, 103]. In contrast to nebulization, dry powder inhalation (DPI) 
has the traits to reduce expenses of the treatment and it is more convenient to be used.  
In addition, there is no need for storage of the formulation in the fridge as for nebulizers, 
lower contamination probability as it is less influenced by hygienic threats and higher dose 
delivery in comparison to nebulizers is possible [104]. 




Presently, also Bayer and Novartis are investigating in dry powders using an emulsion 
based spray–drying technique called PulmoSphere technology, to create porous particles 
with a sponge-like morphology. Using this technology, tobramycin as DPI has already been 
approved from FDA and ciprofloxacin as DPI is in Phase III clinical development [105]. 
Nevertheless, there is an urgent need to have new classes of inhaled antibiotics, since 
resistance to antibiotics is inevitable. Different classes of antibiotics might serve in a better 
way, as bacteria resistance towards antibiotics could be reduced [106]. Over and above, 
not only antibiotics but also N-acetylcysteine (NAC) has been proven to have bactericidal 
and antimicrobial effectiveness by decreasing biofilm formation and diminishing the 
production of extracellular polysaccharide matrix whilst fostering the disruption of the 
mature biofilm [107]. Furthermore, NAC has a mucolytic effect by cleaving the disulfide 
bonds in mucins leading to a reduced mucus viscosity [108]. Typically, NAC is 
administered in CF via nebulizers demanding more application time and entailing extended 
cleaning efforts. For this reason, manufacturing NAC as (DPI) for inhalation simplifies the 
application for the patient in comparison to nebulizers and can greatly enhance adherence 
to the therapy and therefore increase the effectivity [109]. The CF disease is a very 
complicated illness and requires using different drugs at the same time. These include 
antibiotics, anti-inflammatory agents, mucolytic agents and osmotic material [110, 111]. 
The essential need to combine different drugs for a sufficient therapy has inspired us to 
have all these drugs together in one formulation, with the ultimate goal of achieving an 
extra functional drug application that could potentially decrease symptoms and the severity 
of CF in patients. Recognizing this, we have developed a novel, interesting approach to 
prepare a dry powder formulation (DPI) composed of antibiotics and NAC by utilizing a 
spray drying technique. Based on that, the incorporation of additional drug carriers in the 
inhalable formulation could add another aspect for the treatment of CF such as addressing 








In this regard, the extension of the pulmonary MP system by incorporating a carrier for an 




Fig. 1: Sketch of the anticipated design and composition of the microparticles. 
 
As an example, PLGA NPs loaded with Curcumin as an anti-inflammatory drug could be 
loaded into the matrix which is a mixture of antibiotics and N-acetylcysteine. We hope that 
such a system could ultimately enhance the future treatment for cystic fibrosis. Overall, we 
have described the mechanism of complex formation of NAC/antibiotics. This knowledge 
will give an opportunity to use a variety of drugs to be in an inhaled form as (DPI). This 
could be achieved by exchanging the anionic or the cationic partner with different 
substances that exhibit desired properties. Besides the successful formation of a powder 
formulation for inhalation (next generation impactor) was used to evaluate their flying study. 
Also, their impact on biofilm and mucus were tested. The effect of the formulation on the 
viscosity of mucus was evaluated using pulmonary horse mucus. Furthermore, 
disintegration of MPs was assessed together with the activity of the antibiotic and the effect 












4.3  Material and methods  
4.3.1 Materials 
 
D-mannitol (≥98%) (MW= 182.172 g/mol), N-Acetylcysteine (MW= 163.19 g/mol), L-Leucine 
(MW= 131.18 g/mol), curcumin (MW= 368.39 g/mol), agarose, azithromycin (MW= 748.98 
g/mol), ciprofloxacin (MW= 331.346 g/mol) and tobramycin (MW= 467.515 g/mol) were 
obtained from Sigma Aldrich (Steinheim, Germany). Nitrocellulose membrane was a gift from 
Fisher Scientific GmbH (Schwelten, Germany). Pulmonary horse mucus was obtained after 
BAL of horses. (Pferdeklinik Altforweiler, Germany). 
 
4.3.2 Preparation of multifunctional microparticles 
 
The multifunctional microparticles were produced by using a BÜCHI B-290 Spray Dryer from 
Büchi (Flawil, Switzerland). N-Acetylcysteine (NAC) was dissolved in Milli-Q water and one 
of the antibiotics was also dissolved under magnetic stirring in Milli-Q water, then NAC 
solution was added slowly into the antibiotics solution in molar ratios. The mixed solution 
was left for 10 min until the solution became clear (Table 1) and L-Leucine was also added. 
 
The amount of L-Leucine was determined in preliminary studies. The mixed solution was 
adjusted to gain an overall concentration of all solid substances together of 1 wt. % for spray 
drying. The spray dryer was assembled and the settings were adjusted to fit the spray drying 
conditions. The gas rotameter was set to 50 mm which translates to an actual air volume 
flow of roughly 1050 L/h, peristaltic feeding pump was set to 10% (~ 3 mL/min of spray 
drying solution feed) and the aspirator was set to 100% which stands for an approximate gas 
flow rate of 35 m3/h. 
 
Table 1: Amount of NAC and antibiotic in the spray drying solution with the needed percentage of L-
Leucine. 
Formulation NAC [mol] Antibiotic [mol] L-Leucine [%] 
AziNAC 2 1 5 
CiproNAC 1 1 10 
TobraNAC 5 1 10 




All mixtures were spray dried with compressed air. After spray drying, the obtained powders 
were collected and stored in a desiccator at room temperature. All formulations were spray 
dried in triplicate. 
4.3.3 Morphology of the multifunctional microparticles  
 
For morphology analysis, a scanning electron microscope EVO HD 15 from Zeiss (Jena, 
Germany) was used. Each of formulation was spread on an individual carbon disc and 
sputter-coated with a 10 nm gold thin layer using a Quorum Q150R ES sputter coater 
(Laughton, UK). 
4.3.4 Determination of in vitro aerodynamic behavior 
 
For examination of the aerodynamic properties, the (DPI) formulations were applied on a 
Next Generation Impactor (NGI) from Copley Scientific (Nottingham, UK). Before the 
experiment, the impactor pans were coated with a Brij-Coating consisting of 4 parts 15% 
Brij 35 in Ethanol in 6 parts glycerol; 10mL of Milli-Q water was filled in the pre-separator. 
For every experiment, a hard gelatin capsule (size 3) was filled with approximately 20 mg of 
formulation. The capsules were placed in a HandiHaler (Boehringer Ingelheim, Ingelheim, 
Germany) and pierced. The air flow for application was set to 60 L/min and controlled by a 
M1A flowmeter (Copley Scientific, Nottingham, UK). The active time of the vacuum pump 
(Erweka, Heusenstamm, Germany) and the critical flow controller (Erweka, Heusenstamm, 
Germany) was 4 seconds. After running the experiment, the powder contents in the NGI 
pans were dissolved in a defined amount of water and the fluorescence signal of Rhodamine 
B was analyzed using a Tecan reader infinite 200 (Tecan, Männedorf, Switzerland). 100 µL 
of a 5 mg/mL Rhodamine B-ethanol solution was added for each 100 mg of dry substance in 
the feeding solution for spraying. For each formulation, an individual calibration curve was 
prepared and the whole formulation was analyzed using an excitation wavelength of 565 nm 
and an emission wavelength of 625 nm. All experiments have been carried out in triplicates 
under the same conditions. 
 
 




4.3.5 Disintegration behaviors of multifunctional microparticles 
 
0.1% Agarose gel was prepared by dissolving it in hot water for 30 min and pouring the 
solution into Petri dishes. The gel was left overnight to cool down. Spray-dried microparticles 
(SD-MP) were spread on top of a nitrocellulose membrane by using a Penn-Century device 
(Wyndmoor, USA) in order to obtain a better distribution over the filter. Then, the 
nitrocellulose membrane pieces were placed on top of the gel pad for a pre-determined 
amount of time (0 min, 10 min, and 30 min) to determine the disintegration behavior of the 
matrix over time. After the experiment, the membranes were removed from the gel pads. 
Then, it was analyzed through using SEM after sputter coating (EVO HD15, Zeiss, Jena, 
Germany). All experiments were executed in triplicate. 
 
4.3.6 Determination of the rheological properties of mucus after multifunctional 
microparticles application 
 
The viscoelastic property of pulmonary horse mucus in the presence of formulations was 
determined by a rotational viscometer Kinexus (Malvern, UK). Pure pulmonary horse mucus 
(Pferdeklinik Altforweiler, Germany) without treatment with the MPs was measured as a 
control. 500 µL of mucus was treated with 100 µl solution of formulations after adjusting the 
content of NAC inside the formulation as (0.1%) for 30 min followed by measuring the 
viscous behavior using cone-plate geometry with 1° and 0.5° angle (C60/1, C60/0.5) at 
different shear stress rates range of (0.02 – 2 Pa). Measurements were performed at room 
temperature in triplicates. 
4.3.7 Stability of the multifunctional microparticles 
 
For stability analysis, a scanning electron microscope EVO HD 15 from Zeiss (Jena, 
Germany) was employed. For each formulation, 3 batches were prepared. One was stored 
in a desiccator in presence of silica sand at room temperature and one was stored in the lab 
at room temperature and in the dark. These storage conditions were chosen to enable a 
comparison between microparticles that were stored at dry conditions and at ambient/humid 
conditions. The formulations were investigated regarding their stability directly after fresh 
preparation, after 3 weeks and 3 months.  





4.3.8 Influence of the multifunctional microparticles against Pseudomonas 
aeruginosa biofilm assay 
Determination of MPs’ effects on the overall biofilm mass was performed using the crystal 
violet (CV) assay according to reported procedures with a slight modification [26, 27]. P. 
aeruginosa PA14 strain was cultivated in 96 well plates using PPGAS medium. 2 µL of the 
MPs stock solution was added to 198 µL of the bacterial culture to give 200 µL total volumes 
(final concentration equals 1% of stock solution concentration). DMSO 1% was used as a 
control. Experiments were performed at least in duplicates. Graphical illustrations of the 
results represent the mean values and error bars denote the standard deviation. 
4.3.9 Extracellular DNA (eDNA) assay 
 
The impact of MPs on eDNA was assessed as previously reported [112] [113] via incubation 
of biofilm with propidium iodide solution (0.05 mg/mL) at 37 °C for 24 h and detection of 
specific fluorescence at 620 nm after a thorough washing step with 18MΩ H2O. 
4.3.10 Antibacterial assay 
 
Determination of growth inhibitory effects and minimum inhibitory concentrations (MICs) for 





















4.4  Results and discussion  
4.4.1 Manufacturing and characterization of the spray-dried multifunctional 
microparticles  
 
The research focus was to produce an inhalable dry powder (DPI) formulation with a 
functional matrix for microparticles using N-Acetylcysteine (NAC). The combination of drugs 
and drug carriers with the mucolytic property of NAC seemed to be an interesting target. The 
reduced mucus viscosity shall facilitate penetration through mucus. However, due to the high 
hygroscopicity of NAC, spray drying it into microparticles was not achieved yet [109]. 
Spraying of the pure NAC resulted in strongly agglomerated particles (Fig. 2). 
 
 
Fig. 2: SEM micrograph of pure spray-dried NAC, Magnification 5.000x. 
 
Already, the collection of the spray-dried microparticles of the pure NAC was complicated 
because it solidified as a hard and sticky layer-like structure on the surface of the spray-
dryer’s collector glass. The second attempt was to have microparticles composed out of 
NAC and Mannitol. Mannitol (a sugar alcohol with osmotic characteristics) is one of the most 
commonly used excipients with respect to the treatment of pulmonary infections in CF 
disease [114] [115]. It is FDA approved as mucolytic drug (Bronchitol®) as add-on remedy in 
adult in CF patients. The applied DPI formulation has shown an osmotic effect increasing the 
liquid content of the mucus layer. Subsequently, the viscosity of the mucus is decreased and 
the mucociliary clearance is enhanced [115].  
 




NAC and Mannitol were spray-dried in different ratios. As a reference, pure Mannitol was 
also spray-dried under the same conditions. Looking at their morphology under SEM, it was 
observed that the obtained formulations with a Mannitol:NAC ratio higher than 12:1 showed 
a better morphology with distinct spherical microparticles (Fig. 3). 
 
Fig. 3: SEM micrographs of spray-dried Mannitol/NAC microparticles. 1:1 ratio (A), 12:1(B), 25:1 (C) 
and pure Mannitol as reference (D) at magnification 5.000x. 
 
In addition, the samples were easy to collect and to handle while storing in the desiccator. 
This could be due to the increase of the glass transition temperature of the whole formulation 
by increasing the mannitol content [109]. Several preliminary studies were conducted, to 
understand NAC’s interaction with different chemical properties to increase its concentration. 
However, the only real improvement was observed while mixing NAC with the weak 








Hypothetically, the ionic interaction of the cationic amino groups of CS with the anionic 
carboxylic acid group of NAC might be responsible for this. A second drug used for the 
treatment in CF offering cationic groups such as several antibiotics seemed promising. 
Hence, this unique approach would combine NAC’s mucolytic properties with the microbicide 
effect of antibiotics. However, it was unclear how NAC interacts with the amino groups of the 
antibiotics and how the interaction affects the solubility of the antibiotics. Therefore, NAC 
was combined with Azithromycin (an antibiotic with two free amino groups which has a low 
solubility in water) and dissolved in water. Our preliminary study showed that using an 
equimolar amount of NAC and azithromycin, the aqueous solution was highly turbid and the 
azithromycin was still mostly undissolved. Using a molar ratio of 1:2 of azithromycin to NAC 










Fig. 4: The dry substances of Tobra/NAC, Cipro/NAC & Azi/NAC respectively, show differences in 
dissolving speed upon contact with water. Cipro/NAC takes longer to completely dissolve than the 
other two formulations. Finally, all formulations were clear solutions. Picture was taken 1min after 
contact. 
 
The two ionizable amino groups and the charge ratio of the mixture support the hypothesis 
of the interaction process between the charged groups. To further proof this hypothesis, two 
different antibiotics with different amounts of amino groups were chosen namely 
ciprofloxacin (Cipro) (an antibacterial fluoroquinolone) and tobramycin (Tobra) 
(aminoglycoside antibiotic) also representing different classes of antibiotics.  
 




This means for ciprofloxacin that only an equimolar amount of NAC was necessary due to 
the fact that only the secondary amino group in the piperazine heterocycle is an amino group 
that can be ionized. The other two nitrogen atoms are in a vinylogic interaction with the keto 
groups inside the molecule, for this reason, vinylogic amides are hard to protonate. For 
tobramycin, an already water-soluble antibiotic with five amino groups that are easily 
protonated, a ratio of 1:5 of tobramycin to NAC was chosen. This was done to achieve an 
optimal concentration for salification of NAC within the formulation. These equinormal ratios 
should also allow for stable formulations of the spray-dried powder balancing the high 
hygroscopic potential of NAC. Even though, it would have been possible to spray dry 
tobramycin with less NAC. The ionization of both components together as illustrated on the 
example of NAC interaction with antibiotics in (Fig. 5) should also improve the solubility 
necessary for spray drying from aqueous solution. 
 
 
Fig. 5: Ionization site of antibiotics and NAC for the spray-dried combination 
 
Having the antibiotics in a salt form would also increase its solubility in water and accordingly 
the efficacy of the treatment since it will allow the drug to increase the local concentration at 
the site of deposition [116]. Furthermore, these antibiotics and NAC formulations will be 
available as DPI formulation for inhalation. To counterbalance the hygroscopic properties of 
NAC, L-Leucine was added into the formulations. It showed already the ability to protect 
hygroscopic dry powders from wetting and therefore early disintegration [117].  
 




This effect can be explained by the lipophilic tert-butylic tail of L-leucine which strengthens 
the hydrophobic properties of formulations, prevents water to adsorb at the particle surface 
and to penetrate in the deep layers of the particles. In addition, L-leucine showed that it is 
able to optimize the microparticle morphology by smoothing the surface and reducing 
wrinkles and cracks [117]. The feeding solutions for each antibiotic/NAC formulation were 
prepared as described in Tab. 1. For each amino group, one mole of NAC was added to one 
mole of antibiotic in order to achieve a saturation of all amino groups. The powder mixtures 
were all dissolved in Milli-Q water. Tobramycin in combination with NAC was easily 
dissolved hence it has good water solubility. Besides the low solubility of Ciprofloxacin 
(Cipro), the stoichiometric mixture with NAC (1:1) could be fully dissolved in 1h. For all 
formulations, the same standardized spray drying conditions were used (as indicated 
previously). All three formulations of antibiotic/NAC displayed similar handling properties with 
respect to collecting and storing. This implies low moisture content and low aggregation. As 









Fig. 6: SEM micrographs of spray-dried antibiotics/NAC microparticles. Azithromycin/NAC (A) and 
Ciprofloxacin/NAC (B), Tobramycin/NAC at, 10.000x and 15.000x magnification respectively. 
 
All formulations were consisting of mostly distinct particles. Cipro/NAC and Azith/NAC 
formulations exhibited smoother surfaces than Tobra/NAC, showing a raisin-like shape. 
Finally, as our formulations were spray-dried completely out of pure water without any 
organic solvent, it was also possible to incorporate PLGA NPs and make it more functional. 









4.4.2 In Vitro Aerodynamic Properties  
 
The flying properties of particles are an extremely important criterion when developing a 
novel formulation for inhalation. Particles with a diameter bigger than 5 µm mainly deposited 
in the oropharynx and large conducting airways, whilst particles ranging from 1 to 5 µm 
would be deposit in the small airways and alveoli. Thus, the aerodynamic properties of the 
powder formulations were investigated using the Next Generation Impactor (NGI). The data 
obtained such as the mass median aerodynamic diameter (MMAD), the geometric mean 
(GSD) and the fine particle fraction (FPF) are depicted in table 2. 
 
All formulation containing antibiotics/NAC showed a proper FPF of at least 60% and 
comparable MMAD values ranging between 2.16 up to 2.63 µm. The innovated pulmonary 
microparticles have exhibited appropriate aerodynamic properties for a treatment of chronic 
lung infections in cystic fibrosis. 
4.4.3 Disintegration behavior of the multifunctional microparticles in humid air 
 
For microparticles intended for inhalation purpose, an appropriate disintegration rate of the 
matrix is crucial. Upon deposition into the lungs, a rapid disintegration in the small available 
amount of fluid is desired [114]. The combination of the antibiotics with NAC revealed 
already for spray drying the positive effect of the complex formation as also the drugs with 
low solubility (azithromycin and ciprofloxacin) became water soluble after spray drying. To 
investigate the dispersibility, DPI formulations were applied onto a filter membrane in 100% 




Table 2: Results of the NGI evaluation of the spray-dried powders, SD is provided in brackets. 
 Cipro/NAC Tobra/NAC Azi/NAC 
MMAD [µm] 2.40 (± 0.02) 2.16 (± 0.33) 2.63 (± 0.03) 
GSD 1.88 (± 0.008) 1.53 (± 0.06) 1.64 (± 0.13) 
FPF [%] 61.60 (± 5.23) 97.52 (± 15.36) 67.40 (± 9.41) 




The fate of the particles on the membrane was visualized using SEM. As a control, 
microparticles without placing on agarose pads were examined. As can be seen in (Fig. 7), 
the microparticles started to dissolve immediately (t =0 min) after placing them on the 
















Fig. 7: SEM micrographs of spray-dried microparticles deposited on top of a nitrocellulose membrane 
(A) formulation without placing ontop of agarose Pads. (B) antibiotics/NAC at 0 min when got placed 
on top of Agarose pads, antibiotics /NAC at 30 min (C) at 5.000 x,10.000 and 15.000x magnification 
respectively 
 
These results confirmed that the presence of NAC inside the matrix allowed improving 
solubilisation of the antibiotics based on the salification process [116, 118]. Also, in this 
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4.4.4 Effect of NAC-containing multifunctional microparticles on mucus  
  
Mucus and especially the viscous mucus in CF reduce the permeability of drugs and drug 
carriers. Therefore, a mucolytic agent such as NAC is used to fluidize the thick mucus and 
enhance the permeation [119]. The viscosity of pulmonary horse mucus before and after the 
treatment with a solution of the multifunctional microparticles was measured, to assess 
NAC’s influence on the rheological properties of mucus. Applying the antibiotic/NAC 
microparticles to mucus assuming complete dissolution as investigated before reveals 
altered rheological properties of mucus (Fig. 8). Mucus was diluted with pure water in the 
same amount of solution of microparticles which would be applied later in order to avoid the 
dilution effect. The diluted mucus in water was taken as control. Then, Pure NAC as a 
solution was added to undiluted mucus, to assess the effect of the NAC alone on the 






















It was shown that presence of pure NAC, led to a pronounced reduction in the viscosity from 
60 Pa.s to 18 Pa.s. Due to the fact that NAC cleavage the disulfide bond in mucin within 
mucus [107]. Final steps were to assess the effect of NAC within multifunctional 
microparticles. Each formulation after dissolving it was added to mucus. Results showed that 
the presence of NAC inside the formulation, displayed also a reduction in the viscosity of 
mucus from 60 to 19 Pa.s after the treatment by the multifunctional microparticles. The effect 
of the formulation was approximately the same as pure NAC, confirming the efficacy of NAC 
as a mucolytic agent inside multifunctional microparticles. 
4.4.5 Stability of spray-dried multifunctional microparticles 
 
Particle stability under storage conditions is crucial when preparing a dry powder 
formulation. Agglomerated powders, sticky materials or wetted formulations greatly decrease 
the proper application and have a huge effect on the therapy efficiencies. The stability of 
antibiotics/NAC formulations were tested by visualizing them in SEM after several time steps 
(freshly prepared, after 3 weeks and 12 weeks) to determine, whether the formulations are 
stable and distinct particles still remain or start to show any sign of agglomeration. As can be 










































Fig. 9: SEM micrographs of spray-dried of (A) Cipro/NAC, (B) Azith/NAC, (C) Tobra/NAC after 3 










Azthi/NAC and Tobra/NAC formulations were stable under both storage conditions (in the 
desiccator and in a drawer), with distinct particles and smoothly spherical shape. 
Surprisingly, in the case of Cipro/NAC, a rough shell structure as from recrystallization 
appeared on the MP. Which might be related to the presence of NAC and it is perhaps 
because of a kinetic instability of ciprofloxacin. The structure gives the impression of being 
the NAC started to separate from the ciprofloxacin and diffuse out on the surface of the MP 
as illustrated in (Fig. 9 A). The same scenario was observed after 3 weeks up to 12 weeks. 
No further changes could be monitored. As azithromycin and tobramycin were stable and did 
not show any change in the morphology (Fig. 9). Although a change in surface morphology 
could be seen (due to recrystallizing) of Cipro/NAC, still distinct microparticles with no 
agglomeration can be observed (Fig. 9 A).  
4.4.6 In vitro evaluation of the effect of multifunctional MP against biofilm  
 
A key parameter of the microparticles formulation (MP) is to have a decisive role against 
pathogenic bacteria. Pseudomonas aeruginosa biofilm is a community of bacterial cells 
embedded in a mixture of biopolymers, e.g., polysaccharides, proteins, lipids, and 
extracellular DNA (eDNA) forming the biofilm matrix [26]. These extracellular polymeric 
substances (EPS) have structural, nutritional, and protective functions in the biofilm. 
Extracellular DNA is a main component of P. aeruginosa biofilm matrix. It plays an important 
role in biofilm formation, virulence as well as antibiotic resistance [120-122]. Antibiofilm 
activity of the MP formulations against the highly virulent clinical isolate P. aeruginosa PA14 
was evaluated by two methods: crystal violet (CV) biofilm assay [123] [112] and eDNA assay 
[112, 113]. Azithromycin-NAC MPs showed a synergistic effect on biofilm (25% inhibition) at 
a concentration of 0.3 µg/mL, while neither azithromycin nor NAC separately showed 
inhibition at the same concentration (Fig. 10A). 
 





Fig.10: Effects of azithromycin, NAC, and azithromycin-NAC MP at concentrations of 0.3 and 10.0 
µg/mL on biofilm (A) and eDNA formation (B) in P. aeruginosa PA14. 
 
At a concentration of 10 µg/mL, comparable inhibitory effects of azithromycin-NAC MPs and 
azithromycin alone were observed (Fig. 10A). This can be attributed to the antibacterial 
effect of azithromycin at 10 µg/mL concentration. Similar results were obtained from eDNA 
assay. Combination of azithromycin and NAC in the MPs resulted in 30% inhibition of eDNA 
formation at 0.3 µg/mL, whereas neat azithromycin showed no inhibition at the same 
concentration (Fig. 10B). Equal inhibitory effects of the MPs and azithromycin were observed 
when the concentration of azithromycin exceeded the minimum inhibitory concentration 
(MIC) (Fig. 10B and Table 1 for the antibacterial activity). This might be due to the strong 
antibacterial effect not profiting from the presence of NAC. Both ciprofloxacin and 
ciprofloxacin-NAC MPs showed about 65% inhibition of biofilm at 0.1 µg/mL and nearly full 
inhibition at 0.3 µg/mL, whereas NAC alone showed no inhibition at the equivalent 
concentrations in both MP formulations (4.9 and 15 µg/mL, respectively) (Fig. 11A). 
 
Fig. 11: Effects of ciprofloxacin, NAC, and ciprofloxacin-NAC MP at concentrations of 0.1 and 0.3 












The equal potency of ciprofloxacin and ciprofloxacin-NAC MPs can be attributed to the 
antibacterial effect of ciprofloxacin at concentrations of 0.1 and 0.3 µg/mL (see Table 3 for 
the antibacterial activity), which may mask partially or completely the effect of combination 
with NAC. Results of eDNA assay are in line with the biofilm assay. Notably, the inhibitory 
effects of ciprofloxacin-NAC MPs and their individual components on eDNA formation are 
more pronounced (Fig. 11B). At concentration of 0.1 µg/mL, no significant inhibition of 
biofilm formation was observed for tobramycin, NAC, and the corresponding MPs (Fig. 12A). 
Interestingly, tobramycin-NAC MPs showed a synergistic effect on biofilm inhibition at 
concentration of 0.3 µg/mL compared to each ingredient alone (Fig. 12A). 
 
Fig. 12: Effects of tobramycin, NAC, and tobramycin-NAC MP at concentrations of 0.1, 0.3, and 10.0 
µg/mL on biofilm (A) and eDNA formation (B) in P. aeruginosa PA14 
 
 At a concentration of 10 µg/mL, both tobramycin and tobramycin-NAC MPs exhibited almost 
total inhibition of the biofilm (Fig. 13A). As mentioned above, interference with the antibiofilm 
effects occurred at high concentration of tobramycin due to inhibition of the bacterial growth 
of the drug (see Table 3 for antibacterial activity). Effects of the tobramycin-NAC MP 
formulations on eDNA showed the same profile as their biofilm activities (Fig. 13B). Worth 
mentioning that in all MP formulations, concentrations of NAC used are much lower than that 
was required to affect the biofilm of P. aeruginosa PAO1 (500 – 2500 µg/mL) [107]. This was 
reflected in the antibiofilm activity, where the NAC alone did not show biofilm inhibition 
(Figure 11A, 12A, and 13A), and only a moderate effect on eDNA formation (Figure 11B, 










In contrast, synergistic effects were observed when NAC was combined to azithromycin or 
tobramycin at a concentration of 0.3 µg/mL (Figure 11A and 13A). Taken together, these 
results demonstrate that the new combinations in the MP formulations especially those of 
azithromycin and tobramycin have a beneficial effect on biofilm elimination. 
4.4.7 Effect on antibiotic susceptibility 
 
The antibacterial activity against the clinical strain P. aeruginosa PA14 was determined for 
the antibiotic-containing MPs and the antibiotics alone at the same concentration as in the 
MPs (Table 3). Susceptibility to the macrolide antibiotic azithromycin has slightly increased 
by the MPs formulation. For the fluoroquinolone antibiotic ciprofloxacin, no significant 
difference between the minimum inhibitory concentration (MIC) value of the MPs and the 
neat antibiotic was observed (MIC values: 0.05 µg/mL vs. 0.06 µg/mL, respectively). 
Interestingly, the NAC concentration used in this formulation did not negatively affect the 
MIC value of ciprofloxacin against P. aeruginosa PA14 in contrast to a previous finding [124]. 
Similarly, the growth inhibitory activity of the aminoglycoside tobramycin was not affected by 
the MPs ingredients 
 
Table 3: Antibacterial Activities of the Antibiotics with (MP +) and without (MP -) Microparticles. 
Antibiotic Concentration  P. aeruginosa PA14 % growth inhibition or MIC (µg/mL)  
MP - MP + 
Azithromycin 0.3 µg/mL 25% 36% 
Ciprofloxacin 0.1 µg/mL 0.06 0.05 
Tobramycin 0.1 µg/mL n.i.a n.i. 
Tobramycin 0.3 µg/mL 10% 10% 












4.5  Conclusion 
 
Respirable multifunctional microparticles for inhalation composed of different antibiotics 
and N-Acetylcysteine as the matrix was successfully developed. The formation of counter 
ion complexes between antibiotics belonging to different classes and NAC allowed for 
improving solubility of the antibiotics. This allowed for the successful formation of a powder 
formulation using spray drying. In addition, an effect on the redispersibility of the particles 
at 100% relative humidity was also observed. The shelf-stability of these particles was 
investigated with respect to their morphology and agglomeration behaviour revealing stable 
particles for Azithromycin/NAC and Tobramycin/NAC over a range of 12 weeks. Obviously, 
the formation of the counter ion also reduced the hygroscopicity of the system contributed 
by NAC. In addition, the obtained spray-dried powders of antibiotic/NAC have shown good 
aerodynamic properties with fine particle fractions above 60%. An application to the lung is 
possible since the combined effect of NAC plus the antibiotic has reduced mucus viscosity 
and allows a direct treatment of residing bacteria. Moreover, the combination of antibiotics 
and NAC has allowed us to present a novel dry powder formulation for the used route of 
administration (inhalation) for NAC. By bringing more insight into the mechanism of 
salification, this might offer help to other drugs to be formulated for inhalation. Beyond the 
innovative matrix, there is a possibility for further milestone to be developed by loading the 
MP with a different kind of drug which will be loaded into NPs where a different approach 
for treatment would benefit from the combination therapy. Moreover, the antibiotic-NAC as 
MP formulations showed synergistic inhibition of biofilm and eDNA formation for 
azithromycin and tobramycin at 0.3 µg/mL. The new MP formulations showed a slight 
enhancement of the azithromycin susceptibility against P. aeruginosa PA14, and they 
retained the antibacterial activities for all tested antibiotics. 
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5. Multifunctional inhalable microparticles combining antibiotics and a 




Nowadays, the resistance of bacterial biofilms towards the current antibiotics is a serious 
problem. Therefore, so many efforts were devoted for developing new formulations using 
nanotechnology. Here, we have innovated 3 novel multifunctional formulations using spray 
drying technique made of multiple drugs namely Antibiotics, NAC, and Curcumin-loaded 
PLGA NPs. The microparticles were characterized in terms of size, morphology, and flying 
properties. Moreover, the microparticle formulations have been assessed for its cell viability 
with macrophage-like cells. The cells were viable after 20h interaction in a concentration 
range of 1-135 µg/mL of the antibiotics. From this range, the antibacterial activity of free 
drugs versus drug in the formulations was evaluated on P. aeruginosa and its killing was 
achieved within   30 µg/mL (MIC50) for azithromycin and less than 1 µg/mL for ciprofloxacin 
(MIC90), without differences in relation to the spray dry formulation. However, Tobra/NAC 
microparticles have increased the sensitivity of Tobramycin by 3.5-fold compared to the free 
drug. Bacteria-derived inflammation was not inhibited by free antibiotics, except on the 
inhibition of TNF-α. However, NAC and the addition of Curcumin-loaded PLGA NPs 
















5.2  Introduction  
 
From individual cells to dense communities, bacteria have stages of adaptation onto biotic or 
abiotic, static or moving surfaces. The community phase is called biofilm, in which the 
aggregation of bacteria in combination with extracellular polymeric substances (from 
extracellular DNA, proteins to alginate) forming its surrounding matrix [125]. Formation of 
biofilm is ubiquitous and is also of huge relevance for patients influencing the development 
of diseases. [126]. In Cystic Fibrosis (CF), the protection characteristics of the lung 
maintained by macrophage clearance, mucociliary escalator, and composition of surface 
lining antimicrobial fluid [127-129] are altered due to the highly viscous mucus as a result of 
the defective CFTR gene. This contributes to increased bacterial adherence that translates 
to biofilm formation, causing host response to be strong accompanied by a local increase of 
cytokines production and excessive recruitment of neutrophils [130]. Overall, a comprised 
immune system, the increased bacterial virulence, and the development of drug resistance 
which is connected to the hampered penetration through mucus and biofilms lead to reduced 
quality of life for CF patients [126]. Infections are derived from biofilm-forming bacteria like 
Pseudomonas aeruginosa and Staphylococcus aureus. In Europe, about 10-60% of CF 
patients are associated with chronic P. aeruginosa. Furthermore, 64% of fatalities were 
caused due to the bacterial infection in the respiratory tract [131, 132]. Effects against 
biofilms can be observed by the amount of biofilm formed (biofilm inhibition) or treatment of 
mature biofilms (eradication) [133]. Biofilms are a kind of hydrogel offering a certain pore 
size for penetration [27]. In addition to this, the biofilm might be incorporated in mucus also 
being a gel-like system restricting penetration by interaction filtering and size filtering [18, 
134]. However, using nanotechnology is assumed to facilitate drug delivery due to the small 
size and the adjustable surface chemistry, allowing for the avoidance of the interaction with 
for example the high viscous mucus in cystic fibrosis [27, 135]. Nanoparticles (NP) will 
protect the drug and their small sizes will enable to deliver it in the mucus and biofilm and 
thus to the microorganisms [17, 135].  
 




This will potentially decrease the side effects while increasing the direct interaction with the 
pathogenic microorganisms [17, 136]. Still, the existence of the defense mechanism against 
particles such as size-filtering and interaction-filtering effects will limit the efficiency of the 
therapeutic drug. Nevertheless, nanoparticles in a range from 1 to 500 nm are considered 
too small in order to be applied efficiently into the lungs as an inhalable powder [29, 137]. 
Microparticles in the range of 1µm up to 5µm are considered optimal to ensure their 
deposition into the lower part of the respiratory system without being exhaled [138-140]. The 
combination of the necessary aspects for inhalation and mucus/biofilm penetration can be 
achieved by spray drying of nanoparticles using a suitable matrix [114, 141, 142]. The most 
challenging aspect for producing inhalable formulations is choosing an appropriate matrix to 
embed the particles which later on could be dispersible within the lung. [143, 144]. Up to 
now, the conventional way to formulate inhalable formulation out of the nanoparticulate is to 
use materials such as lactose or mannitol as a matrix to embed this nanoparticulate within it 
[145]. Previously, we have developed an innovative matrix for inhalation as a dry powder, by 
combining (antibiotics and N- acetylcysteine) as multifunctional drug delivery system [146]. 
The idea was to make use of ionic interactions between the acid group in NAC and the free 
basic amino group(s) in antibiotics, which has enabled us for spray drying the NAC in the 
presence of antibiotics. At the same time the antibiotics solubility has increased. To address 
simultaneously the persistent inflammation in CF patients we have integrated PLGA NPs 
loaded with Curcumin as a natural anti-inflammatory into this innovative matrix [147, 148]. 
Such a multifunctional formulation, combining a co-mixture of antibiotics, the mucolytic N-
acetylcysteine and Curcumin as a natural anti-inflammatory might be a promising approach 
for the future of cystic fibrosis treatment. The combination would potentially increase drug 










Also, using the multifunctional formulation would allow benefiting from local effects of the 
applied drugs instead of the systemic application which will contribute to lower undesirable 
side effects due to using a low dose [149]. 
To address the aspects raised before, the inhalable multifunctional formulation was 
characterized in terms of aerodynamic properties and the geometric sizes and shape using 
SEM. Furthermore, the properties of the nanocarriers, as well as their recovery after being 
embedded into the microparticles (MPs) were investigated. Finally, the permeability of 
Curcumin-loaded PLGA NPs (Cu-PLGA NP) through human pulmonary mucus was 
confirmed using confocal laser scanning microscopy (CLSM). The biological activity of the 
formulation was evaluated using acute toxicity (MTT), the antibacterial activity (MIC) as well 























5.3  Material and methods  
5.3.1 Materials 
 
Polymer (PLGA) (Resomer RG 503H) was obtained from Evonik Industries (Darmstadt, 
Germany). Rhodamine B (as fluorescence label), acetonitrile (ACN), N-Acetylcysteine (NAC) 
(MW= 163.19 g/mol), L-Leucine (MW= 131.18 g/mol), Curcumin (MW= 368.39 g/mol), 
Tobramycin (MW= 467.515 g/mol), Azithromycin (MW= 748.98 g/mol), and Ciprofloxacin 
(MW= 331.346 g/mol) were purchased from Sigma Aldrich (Steinheim, Germany). P. 
aeruginosa strain PAO1 (DSMZ 22644) and THP-1 monocytes (ACC-16) were purchased 
from DSMZ (Braunschweig, Germany) and PAO1-GFP from ATCC (Virginia, USA), while 
ampicillin for GFP expression was bought from Carl Roth (Karlsruhe, Germany). RPMI cell 
medium was obtained from Gibco (Germany), while FCS (fetal calf serum), LB Broth and 
phorbol 12-myristate 13-acetate (PMA) from Sigma-Aldrich (Germany). Assays were 
performed using 96-well plates from Greiner (USA), while ELISA Ready-SET-Go kits from 
Invitrogen (Vienna, Austria) were assayed on Nunc Maxisorp® 96-well plates from 
ThermoFisher (Germany). 
5.3.2 Curcumin-PLGA NP preparation and characterization 
 
Nanoprecipitation was chosen to prepare polymeric PLGA-Cu NPs, using a microfluidic 
system (Labsmith, Livermore, USA). PLGA/Curcumin at a ratio of 9:1 was dissolved in 
acetonitrile (ACN) as organic phase. Then, the organic phase containing PLGA/Curcumin 
and ACN was injected into the middle channel of a microreactor using a syringe pump 
(Harvard Apparatus PHD 2000 Syringe, Holliston, USA) to grant a steady flow. The aqueous 
phase was composed of Pluronic F-68 (0.1 %) dissolved in water. Before injection into the 
side channels of the microreactor, the aqueous phase was filtered using a membrane of 
0.45 mm pore diameter (Millipore, Billerica, USA) to remove undissolved material. To 
guarantee a steady flow, the aqueous phase was injected into the microfluidic chip using a 
syringe pump (Multi Programmable Syringe Pump, wpiinc, Sarasota, USA).  
 
 




The flow ratio was fixed at 0.1 for all preparations, to obtain PLGA-Cu NPs of similar 
physicochemical properties and to reach encapsulation efficiency similar to previous work. 
After formation of PLGA-Cu NPs, NPs were collected from the outlet. The organic solvent 
was removed under stirring (1000 rpm) in a fume hood at RT overnight. Consecutively, the 
excess amount of stabilizer was removed by washing the nanoparticles 3 times with purified 
Milli-Q water using centrifugation at 10,000 g for 30 min (Multifuge X1R, Thermo Scientific, 
Langenselbold, Germany).   
5.3.3 PLGA NP characterization  
 
The shape of the manufactured PLGA NPs was confirmed using EVO HD15 electron 
microscope (SEM) from (Zeiss, Jena, Germany). The accelerating voltage was set to 5 kV. 
For imaging the sample, ~10 µL suspension was dried under ambient conditions on a silicon 
wafer by evaporation. Then the samples were sputtered with a thin gold layer (~10 nm) by 
using a sputter coater Quorum Q150R ES (Quorum Technologies Ltd, East Grinstead, UK). 
5.3.4 Manufacturing of multifunctional inhalable microparticles 
 
The multifunctional inhalable microparticles (MP) were engendered by utilizing a BÜCHI B-
290 Spray Dryer from Büchi (Flawil, Switzerland). For matrix preparation, N-Acetylcysteine 
(NAC) was dissolved in Milli-Q together with an antibiotic (Azithromycin, Tobramycin, and 
Ciprofloxacin) in equimolar amounts. The co-mixed solution was left for 10 min until the 
solution became transparent. In addition to the (antibiotics and NAC), L-Leucine was 
integrated. The optimal amount of L-Leucine was determined in our previous study, table 2. 
Furthermore, Curcumin-loaded PLGA NPs were added making 20% of the final amount. The 
co-mixed solution for spray drying was adjusted to have 1 wt. % of solid substances. Spray 
drying was done with constant settings for all formulations. Particularly, the parameter for 
gas rotameter was set to 50 mm which diverts to current air volume flow of roughly 1050 L/h. 
The peristaltic feeding pump was tuned to achieve 10% which is approximately equal to (~ 3 
mL/min of spray drying solution feed) and the spray rate was adjusted to 100%, as stands 
for an actual gas flow rate of 35 m3/h. 
 




All the formulations were sprayed using compressed air. Ultimately, after spray drying the 
multifunctional formulation, the collected particles were stored in a desiccator at room 
temperature until usage. For each 100 mg of multifunctional formulation, an approximately 
100 µL of a 5 mg/mL of Rhodamine B dissolved in ethanol was added within the feeding 
solution of the spray dryer to allow for quantification and visualization of the formulation. All 
experiments were accomplished at least in triplicate under the same conditions. 
5.3.5 Morphology of multifunctional inhalable microparticles: SEM and particles 
size distribution  
 
For visualization the shape of multifunctional microparticles, a scanning electron microscope 
EVO HD15 from (Zeiss, Jena, Germany) was employed. The multifunctional formulation was 
immobilized on top of an individual sticky carbon disc. To enable the SEM for visualization, 
the sample was sputter-coated with a thin layer of gold (roughly around 10 nm) prior to 
visualization (Quorum Q15R ES, Laughton, UK). The accelerating voltage was 5 kV for all 
formulations. Images were analyzed in terms of geometric particle sizes utilizing ZEN 2012 
(blue edition) software (Zeiss, Jena, Germany). In addition to SEM, particle size distribution 
was executed using static laser light diffraction with a HORIBA LA-950 (HORIBA Europe 
GmbH, Darmstadt, Germany). The experiment was conducted using a multifunctional 
powder formulation under dry condition directly without any solvent. The sample was 
exposed to vibration and air suction allowing the powder to disperse before crossing the 
laser beam for analysis. 
5.3.6 Examination the aerodynamic properties of multifunctional microparticles 
 
Aerodynamic properties of all multifunctional inhalable formulations were investigated 
utilizing a Next Generation Impactor (NGI) (Copley Scientific, Nottingham, UK). Prior to each 
experiment, the impactor pans were plated with a Brij-coating made up of 4 parts, containing 
15% Brij 35 in ethanol in six parts of glycerol; 10mL of purified Milli-Q water was filled in the 
pre-separator. In each experiment, a gelatin capsule size 3 was filled with approximately 
20 mg of powder formulation. 
 




Then the capsule was placed in a HandiHaler (Boehringer Ingelheim, Ingelheim, Germany) 
and then it was punctured. In more detail, the air flow parameter was adjusted to 60 L/min 
realized by a M1A flowmeter (Copley Scientific, Nottingham, UK). 4 seconds were set for the 
active time of the vacuum pump (Erweka, Heusenstamm, Germany) and the critical flow 
controller (Erweka, Heusenstamm, Germany) as well.  At the end of the experiment, the 
multifunctional inhalable powder formulation within the NGI pans was dissolved in a defined 
quantity of water and analyzed with a Tecan reader infinite 200 (Tecan, Männedorf, 
Switzerland) to detect the fluorescence signal of Rhodamine B (ex = 565 nm and 
em = 625 nm). An individual calibration curve was performed separately for each 
formulation. All multifunctional inhalable formulations were accomplished in triplicates under 
constant conditions. 
5.3.7 Distribution of PLGA NPs in microparticles  
 
The internal composition of the multifunctional inhalable microparticles was observed using a 
confocal laser scanning microscope (Zeiss LSM710, Zeiss, Jena, Germany). The 
multifunctional formulations were spread on top of a nitrocellulose membrane using a Penn-
Century device Model DP-4M (Wyndmoor, USA) to guarantee a good distribution of the 
formulations and then covered by a coverslip. For visualization a 40x (air) objective (Zeiss, 
Jena, Germany) was used. The excitation wavelengths were set with a bandpass filter 
between 458 and 514 nm and detection was accomplished with other bandpass filters 
ranging from 470-551 nm and 551-703 nm respectively to detect Curcumin and rhodamin B. 
5.3.8 Recovery of PLGA-Cu NPs out of microparticles 
 
The redispersability of PLGA NPs after being integrated into the microparticle matrix was 
measured utilizing Zetasizer Nano ZS90 (Malvern Instruments, Worcestershire, UK), to 
evaluate the influence of spray drying process on the nanoparticles size. For each 
formulation, 100 mg of the formulation was dissolved in 1 ml of Milli-Q water, after 10 s 
vortexing. Both, the PLGA NPs size and the PDI of released NPs from the microparticles 
were measured in DLS with a scattering angle of 173°. Every formulation was tested at least 
3 times while keeping the conditions constant. 




5.3.9 The permeability of PLGA-Cu NPs through pulmonary human mucus  
 
The ability of PLGA-Cu NPs to penetrate the mucus barrier and potentially deliver their 
payload was tested using a confocal laser scanning microscope (CLSM) (Zeiss LSM710, 
Jena, Germany). 5 µg of each multifunctional inhalable microparticle formulation was placed 
on top of 40 µL of human pulmonary mucus using a Penn-Century device Model DP-4M 
(Wyndmoor, USA) to ensure homogenous distribution of multifunctional microparticles on the 
mucus layer. Each 40 µL of mucus was stained unspecifically with 1µL of AlexaFluor488-
labelled wheat germ agglutinin [150] and the PLGA-Cu NPs were covalently labelled with 
rhodamine. For assessing the permeability of the PLGA-Cu NPs through the human 
pulmonary mucus, the fluorescence signal of labelled PLGA-Cu NPs was tracked using 3D 
time laps imaging z-stacks. This was after the NPs were released from the disintegrated 
microparticle matrix. Labelled human pulmonary mucus was detected while using 
ex = 488 nm and a detection range between 467−554 nm. The PLGA-Cu NPs were excited 
at ex = 561 nm and the signal was collected in a wavelengths range of 624−707 nm. Directly 
after spray drying the formulation, the permeability of PLGA-Cu NPs within human 
pulmonary mucus was conducted at time points from 0 min up to 1 h for all formulations. All 
experiment was accomplished in triplicate under the same conditions. 
5.3.10   Cultivation of Pseudomonas aeruginosa (PAO1-GFP) and infection of 
THP1 macrophages 
 
P. aeruginosa strain PAO1 (DSMZ 22644) and the fluorescently labeled strain ATCC® 
10145GFP™ were grown in LB broth (Sigma-Aldrich, Darmstadt, Germany) which was 
supplemented with necessary antibiotics (300 μg/mL ampicillin for GFP expressing strain; 
Carl Roth, Karlsruhe, Germany). Overnight cultures were grown by inoculating 15-20 mL of 
LB broth with a single colony of bacteria and incubating the broth for 16-18 hours at 37°C 
and 180 rpm. For infection, an overnight culture of PAO1 in exponential growth phase was 
centrifuged (10min; 2800g) washed with PBS, and diluted to a final OD600 of 0.2 (~ 2x107 
CFU/mL) in RPMI medium. THP-1 cells were infected with PAO1 for 1 hour, and treated for 
6 hours with the above mentioned formulations as well as free drugs. 
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Infected cultures, treated or not, were incubated for 6 hours under static conditions at 37°C 
then centrifuged at 1792 g for 5 minutes. The supernatant was separated for analysis of 
cytokines and filtered MilliQ water was added to the well for cell lysis and freezing at -20°C 
for later use in CFU assay. 
5.3.11 Minimal Inhibitory Concentrations (MIC)  
 
Overnight culture of PAO1 in exponential growth phase was PBS-washed and diluted to a 
final OD600 of 0.2 (~2x107 CFU/mL) in LB broth. Free drugs, material, and formulations 
were weighed and stock solutions were prepared either in DMSO or filtered MilliQ water. 
One hundred microliters of bacterial suspension was mixed with 100 µL of the formulations 
on a 96-well plate. Treated and non-treated bacteria were allowed to grow under static 
conditions for 24 h at 37°C. Optical density (OD 600) was measured with a 
spectrophotometer (Multiskan GO, Thermo Fisher Scientific, Vantaa, Finland). 
5.3.12   Measurements of IL-8, TNF-α and IL-1β by ELISA from infected 
macrophages 
 
Cytokines ELISA Ready-SET-Go kits (Invitrogen, Vienna, Austria) were used with 
supernatant of infected cultures, and the samples processed and analysed following the 
manufacture instructions. Briefly, Nunc Maxisorp® 96-well plates were coated with capture 
antibody of the respective cytokine and incubated overnight at 4 °C. A series of washing 
steps were performed with Wash Buffer (PBS/Tween20 0.05%). Then the wells were 
blocked by incubation with ELISA/ELISPOT diluent for 1 h. Samples were applied (or 
previously diluted, in the case of IL-8 plates) together with cytokine standards and plates 
were incubated overnight at 4 °C. Plates were washed, then received detection antibody of 
the respective cytokine for 1 h incubation at room temperature. Another series of washing 
steps was performed and plates received Avidin-HRP for detection of biotinylated antibodies 
for 30 minutes. The last series of washing steps was performed and 3,3',5,5'-
Tetramethylbenzidine (TMB) solution was applied as enzymatic/colour inductor from the kit. 
Reaction was stopped with 1M H3PO4 solution and absorbance was measured at 450 nm for 
detection and 570 nm as background. Values were paired with an internal calibration curve 
from the cytokine standards. 




5.4  Results and discussion  
5.4.1 PLGA nanoparticles loaded with Curcumin    
 
PLGA nanoparticles loaded with the hydrophobic drug Curcumin (as a natural anti-
inflammatory) were prepared using nanoprecipitation in a microfluidic system. The PLGA-
Cu-NP exhibited a small mean hydrodynamic diameter of around 105 nm with a narrow 
monomodal size distribution (PDI < 0.1) (Table 1). The small sizes and narrow size 
distribution can be attributed to the usage of short mixing time. This approach enabled us to 
control sizes of physiochemical identical PLGA-Cu NPs, yielding also, a high drug 
encapsulation efficiency of 68% (for Curcumin). The zeta potential of PLGA-Cu NPs was a 
slightly negative charge (-10 mV). 
Table 1: Physicochemical characterization of curcumin loaded into PLGA nanoparticles. Values are 
indicated as mean ± SD (n = 3). 
 
Size (nm) PDI Zeta potential (mV) Encapsulation efficiency  
105 ± 1.5 0.063 ± 0.019 − 9.1 ± 4.6 68 % ± 7.6 
 
5.4.2 Manufacturing and characterization of multifunctional inhalable 
microparticles  
 
Previously, we had demonstrated that we could very successfully spray dried microparticles 
composed of an antibiotic and a mucolytic agent (NAC) as dry powder matrix. Now, the 
spray dried powder microparticles were taken to the next stage of innovation and were 
additionally loaded with PLGA NPs as a carrier for a drug of different polarity. For this 
purpose, Curcumin was loaded into PLGA NP which was stabilized by the muco-inert 
stabilizer (Pluronic F-68). Curcumin was selected as an additional drug due to its anti-
inflammatory properties. This ensures that the multifunctional formulation can cover the 
whole spectrum of recommended drugs in CF co-therapy namely antibiotics, mucolytic 
agents and anti-inflammatory compounds [151]. The spray drying feed solution was 
prepared with 20% NPs content of the total weight as it was reported to be an optimal 
fraction of PLGA NP for redispersion [114]. 
 




The obtained multifunctional formulation after embedding the NPs has shown no change in 
handling (very easy to collect) as the nanoparticle-free counterparts. Notably, the 
incorporation of PLGA-Cu NPs showed only a minute effect on the morphology of the 
microparticles compared to the spray-dried multifunctional formulation without NPs (Fig 1). 
 
 
Fig. 1: SEM micrographs of spray-dried antibiotics /NAC microparticles. Azithromycin/NAC (A) and 
Ciprofloxacin/NAC (B), Tobramycin/NAC at, 10.000x and 15.000x magnification respectively.




A very distinct structure of multifunctional microparticle (MP) was obtained. Moreover, 
investigation the composition of multifunctional formulation from CLSM micrographs (Fig. 2) 
revealed from the merged images, showing colocalized NP fluorescence and fluorescence 




Fig. 2: Morphology of co-spray-dried microparticles visualized by CLSM; left row shows the 
Matrix/Rhodamine B fluorescence, the second represent the fluorescence of the curcumin 
(nanoparticles) and in the right row the merge of both shown. Scale bar represents 10 µm.




After ensuring the successful preparation of microparticles containing nanoparticles, the next 
step was to estimate whether the PLGA-Cu NPs will be able to recover after the dissolution 
of the multifunctional formulation in water. DLS measurements showed that the PLGA-Cu 
NPs were unchanged (110 nm in diameter, Table. 3). 
 
Table 3: Nanoparticle recovery out of microparticle matrix after the spray drying. 
 
This is an important factor as parameters such as temperature and high pressure in the 
spraying nozzle might contribute to destroying the NPs or result in aggregation of particles. 
The size distribution of the redispersed embedded nanoparticles is still the same as before 
spraying drying with a PDI < 0.1, indicating still a monodisperse distribution and the absence 
of agglomeration. The evaluation was done for freshly prepared samples and after nine 
months of storage. The data underlined the stability of these PLGA-Cu NPs within the 










 NPs size before 
spray drying  
 NPs after      
Spray drying    
(Azith/NAC) 
formulation  










105 nm (± 0.07) 109 nm (± 0.02) 110 nm (± 0.01) 109 nm (± 0.07) 
After 3 month  ---- 110 nm (± 0.01) 110 nm (± 0.04) 110 nm (± 0.05) 
After 6 month ---- 110 nm (± 0.06) 108 nm (± 0.09) 109 nm (± 0.03) 
After 9 month ---- 109 nm (± 0.03) 110 nm (± 0.02) 112 nm (± 0.08) 




5.4.3 Aerodynamic behavior of the microparticles  
 
To obtain particles suited for inhalation therapy, an appropriate aerodynamic behavior is 
necessary. Generally, it is agreed on, that particulates intended for inhalation should offer 
aerodynamic diameters between 0.5 and 5 µm [152]. Consequently, a flying study for all 
multifunctional formulations was conducted using NGI (Next Generation Impactor). The 
formulations have displayed virtually a congruous FPF > 60% for (NAC/Cipro), (Azi/NAC) 
and above 90% for (Tobra/NAC) (Table 4). Moreover, the mass median aerodynamic 
diameter (MMAD) values as an indicator for the size were ranging between 2.16 and 2.63 
µm which should be well suited for inhalation use. No difference in aerodynamic properties 
of Azi/NAC/NPs formulation FPF (68.83 %) in comparison to nanoparticle-free counterpart 
Azi/NAC (67.40 %), it was the same case for the Cipro/NAC/NPs and Tobra/NAC/NPs 
(Table 4). This implies that adding nanoparticles as an additional carrier did not affect the 
aerodynamic behavior of the formulation. 
Table 4: Results of the aerodynamic properties of spray-dried formulation with NPs and without NPs 
as determined by NGI. 
 
Formulation  MMAD [µm] GSD FPF [%] 
Cipro/NAC 2.40 (± 0.02)   1.88 (± 0.008) 61.60 (± 5.23) 
Cipro/NAC/NPs 2.56 (± 0.04) 1.62 (± 0.02) 64.48 (± 3.22) 
Tobra/NAC 2.16 (± 0.33) 1.53 (± 0.06)   97.52 (± 15.36) 
Tobra/NAC/NPs 2.43 (± 0.15) 1.47 (± 0.24)    87.21(± 8.63) 
Azi/NAC 2.63 (± 0.03) 1.64 (± 0.13) 67.40 (± 9.41) 











5.4.4 In vitro the permeability of NPs through mucus  
 
To profit from the nanoparticle technology to deliver their payload without interaction with the 
surrounding biological barrier such as the viscous mucus in CF, size and surface chemistry 
of NPs need to be controlled [153]. Then, the nanoparticles can play a decisive role in 
overcoming the mucus barrier without being immobilized. Therefore, we have assessed the 
directed diffusion of the PLGA-Cu-NPs through pulmonary human mucus. As shown in figure 
3, the embedded PLGA-Cu- NPs inside the innovative matrix (antibiotic, mucolytic agent) 
has started to show penetration after 15 min. It was the case for all formulations. After 1 h 
there was an increase in signal (red) as an indication for more particles which were able to 
penetrate. It was more or less the same for all formulations as NPs exhibit the same size in 
all formulations.  
 
 
Fig. 3: Confocal laser scanning microscopy study of the penetration of PLGA loaded curcumin NPs 
(red fluorescence) through pulmonary human mucus at predetermined time interval. Mucus was 
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5.4.5 Cell viability via the MTT-Formazan assay 
 
When the formulations take a role as muco-penetrant, its fate will directly affect the host 
lung. So as primary assessment, we used MTT assay to check if the particles and its 
components could bring cell toxicity. THP-1 macrophages were incubated with antibiotic 
concentrations (1-135 µg/mL), either free or incorporated into the formulations. After 
incubaction for 20 h, all formulations with concentrations from 1-30 µg/mL, we observed to 
show around 70% of cell viability. Even so, our proposed formulations include NAC as 
component that alters the pH towards an acidic environment [154], our data shows no 
















Fig. 4: MTT Viability of THP1-macrophages (A) and Minimal Inhibitory Concentration (MIC) of P. 
aeruginosa (B) for free and microparticle formulation of Azithromycin, Ciprofloxacin and Tobramycin. 












5.4.6  Minimal inhibitory concentration of PAO1 P. aeruginosa exposed to 
formulation 
 
Tobramycin, Azithromycin and Ciprofloxacin are known antibiotics and its use has brought 
increased chances on Cystic Fibrosis therapy [155], but the challenge of drug dissolution 
and integration/encapsulation into a targeted formulation is still a challenge in 
pharmaceutical technology. Our formulation placed these antibiotics in combination with 
NAC as mucolytic agent potentially facilitating drug penetration. In all cases, we emphasize 
NAC as co-drug and our data showed no decrease of antibiotic activity, but maintenance of 
the same levels as the free drug. For Azithromycin, MIC50 is reported as 30 µg/mL and for 
Ciprofloxacin concentrations lower than 1 µg/mL achieve P. aeruginosa killing of 80%. 
Tobramycin results point to differences on free drug versus formulation. Our proposed 
formulation increased the sensitivity of P. aeruginosa towards Tobramycin resulting in an 
effective dose 50% (ED50) of 3.4 µg/mL for free Tobramycin and 1 µg/mL for Tobra/NAC 
spray-dried microparticles (Figure 4B). Considering the development of inhalation therapy, 
only tobramycin and aztreonam are approved by the US Food and Drug Administration in 
treating respiratory tract infections [156]. Now, we report the opportunity of 3 new ready-to-
inhale formulations. NAC here is acknowledged as an excipient-drug that is not easy to 
produce with the spray-dryer, muco-penetrating and additive to antimicrobial activity. This in 
advantage against other mucolytics, as mannitol [157], that do not enhance bacteria killing 
on CF infection models and would not help to formulate the microparticles in ionized form. 
5.4.7  Inhibition of inflammation measured via IL-8, IL-1β and TNF-α 
 
After establishing that anti-pseudomonal activity is present, the next step is to address the 
excessive inflammation caused by P. aeruginosa-host interaction. For that, we modelled 
inflammation using P. aeruginosa grown on top of THP-1 macrophages provoking the 
increase by inflammatory markers, here represented by interleukin 8 (IL-8), interleukin 1β 
(IL-1β) and the tumour necrosis factor α (TNF-α).  
 
 




Those levels from the infected samples were used as controls to normalize the percentage 
of inhibition obtained by the combination therapy. The treatment with antibiotics alone did not 






































Fig. 5: Inhibition of inflammation modelled by THP1-macrophages infected with P. aeruginosa treated 
with free N-acetylcysteine (NAC) or free and microparticle formulation of Azithromycin, Ciprofloxacin 
and Tobramycin; with and without co-delivery of Curcumin PLGA nanoparticles. An inherent anti-
inflammatory activity is observed using NAC alone, while the use of Curcumin NP is additive   to the 
inhibition of IL-8 and TNF-α as trends and statistically significant for IL-1β. Statistics comparing 
presence of absence of Curcumin NP is shown as * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
 
Only TNF-α was reduced applying free Azithromycin, Ciprofloxacin and Tobramycin. This 
effect is described in literature and is due to its inhibitory effect on the MAP kinase pathway 
induced by inflammation-inducers as bacterial lipopolysaccharide onto macrophages [158]. 
To increase the anti-inflammatory effect, we integrated PLGA-Curcumin nanoparticles (NPs) 
in the formulation. In Fig 5, the results of Curcumin-NPs co-delivery are observed on the 
grey bars of inhibition on all 3 inflammation markers analysed. The supplementation with 
Curcumin-NPs does not strongly inhibit IL-8 (only around 10%), a main recruiter of 












Nonetheless, with supplementation, the main signs of pro-inflammatory signalling (IL-1β and 
TNF-α) can be statistically inhibited by all three formulations. When comparing free drug 
versus formulation, the advantage of adding PLGA Cu NPs is observed on the reduction of 
IL-1β (20-60%), TNF-α (20-80%), while, for instance, free drugs without Curcumin NP 
supplementation could not inhibit IL-1β.  
Analysing the effect of the applied drugs, the impact of NAC needs to be considered. As 
NAC has been described only recently as anti-inflammatory molecule, but also as corrector 
of chloride efflux on cystic fibrosis cell models [159-161], we used free NAC in three 
concentrations (2.5, 5 and 10 mM) with and without Curcumin-NPs. Inhibition of 
inflammation by free NAC is achieved in a dose-dependent manner: 20-60% inhibition of 
TNF-α and IL-8, and 15% inhibition of IL-1β secretion. These indicate that NAC has more 
benefit than just ionizing the antibiotics and improving the manufacturing process. Yet, this 
inhibition can be increased by the addition of PLGA-Cu NPs into the multifunctional 




















5.5  Conclusion 
 
We achieved the incorporation of Curcumin-loaded nanoparticles into a microparticle 
formulation via spray drying technique. The matrix of the microparticles combined the 
mucolytic agent, N-acetylcysteine in combination with different antibiotics like Tobramycin, 
Ciprofloxacin and Azithromycin. The formulation was done from purely aqueous environment 
and thus a hydrophobic drug could be incorporated using the nanoparticulates. The 
redispersability of the particles PLGA-Cu NPs could be ensured also enabling the system to 
profit from the particles penetration abilities into mucus. Additionally, the inhalable 
microparticles have exhibited a suitable diameter for inhalation FPF above 60 %. Moreover, 
the integration of NAC with relevant antibiotics for CF therapy into a spray-dried 
microparticle was proven to be biocompatible, according to the MTT viability assay, while the 
formulation did not negatively interfere with antibiotics’ activity, but it improved, in the case of 
Tobramycin. The anti-inflammatory effect was more pronounced on the inhibition of TNF-α. 
Combining NAC and the Curcumin-loaded particles could results in a synergistic effect 
showing stronger inhibitory potential as monitored for all investigated cytokines (TNF-α, IL-8 
and IL1however it requires further investigation on the key factors interaction on this 
combination. 
The proposed multifunctional microparticles combine different beneficial aspects for CF 
treatment such as muco-penetration, anti-pseudomonal activity, and anti-inflammatory into 
one inhalable formulation. With such an approach the anti-inflammatory potential could be 
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6. Summary and outlook  
 
Cystic fibrosis is an incurable disease. Therefore, the main treatment relies on symptomatic 
therapy not on the cause of the disease. Currently, the available pharmacotherapy 
treatments are usually a mucolytic agent, antibiotics, anti-inflammatory and osmotic 
material. However, the viscous pulmonary mucus remains a challenging barrier for 
successful treatment of CF as it hinders the permeability of the drugs to reach their site of 
action. Checking the guideline for the treatment of CF, the need of the combination in co-
therapy has inspired us to bring all these functions together and to formulate all of these 
drugs in one, instead of using every drug alone. Therefore, the aim of this thesis was to 
focus on the development of multifunctional formulations for the purpose of inhalation. The 
multifunctional formulations composed out of antibiotics, a mucolytic (N-Acetylcysteine) 
and an inflammatory compound (Curcumin), three kind of formulations were developed 
namely (Cipro, N-Acetylcysteine, PLGA NPs loaded Curcumin), (Tobra, N-Acetylcysteine, 
PLGA NPs loaded Curcumin), (Azith, N-Acetylcysteine, PLGA NPs loaded Curcumin). The 
muco-penetrating PLGA-NPs loaded with curcumin were manufactured using a microfluidic 
technique. A variety of different preparation factors were adjusted in order to study their 
impact on the size of nanoparticles and the encapsulation efficiency of the loaded drug. 
Using the microfluidic technique for preparing the PLGA-NPs has shown to be the most 
successful approach for manufacturing monodisperse small NPs. The NPs were less than 
100 nm with a high encapsulation efficiency of Curcumin EE of ~68% in comparison to the 
conventional nanoprecipitation method. Then, a multifunctional microparticle matrix for 
delivering the PLGA-NPs into the lung was further developed. Based on a salification 
process, the multifunctional matrix (antibiotics, N-Acetylcysteine) was achieved. Benefiting 
from the salification approach, a water-soluble matrix was formulated ensuring fast 
dissolution. Basically, Ciprofloxacin and Azithromycin were not well soluble before 
salification. Salification has converted it from an insoluble drug into a water-soluble drug.




Aerodynamic properties of the formulation were tested using NGI to evaluate the 
deposition of dosed formulation inside the lung. Data has shown guarantor that 
approximately 70 % of multifunctional microparticles are deposited inside the lungs with 
FPF (69 %). The formulations were also in a range between 2.16 up to 2.63 µm which is 
suitable for lung application. The obtained results indicate that the multifunctional 
microparticles have the ability to reach the lungs. A simplified in vitro model to assess the 
disintegration behavior of the multifunctional matrix of microparticles under conditions 
similar to the lungs was developed. The multifunctional microparticles were deposited on a 
surface exposed to a high degree of relative humidity. It was observed that the 
multifunctional microparticles containing (NAC/antibiotics) have already displayed a fast 
disintegration starting from 1 min, as an indication that adding NAC to those antibiotics has 
resulted in a water-soluble matrix. As the multifunctional formulation contains NAC as a 
mucolytic agent, its influence on the macro-rheological of mucus was assessed. The 
rheometer was used to measure the viscosity of the mucus before adding the formulation 
and after adding it (treated and an untreated mucus). It was noticed that the multifunctional 
formulation containing (NAC/antibiotics) resulted in a reduction of mucus viscosity similar to 
free NAC, indicating that NAC was fully active and that it broke the mucin structure of 
mucus. The next step was to evaluate the safety of the multifunctional microparticle in cell 
models, to exclude toxic effects of the particles on human cells. All multifunctional 
microparticles have exhibited a safe profile. Additionally, the effect of the multifunctional 
microparticles against biofilm in P. aeruginosa was tested. The multifunctional 
microparticles containing (NAC/antibiotics) has shown a synergetic effect in comparison to 
free antibiotics, revealing that the presence of the NAC has increased the sensitivity of 
antibiotics towards bacteria, particularly, this was observed in tobramycin formulation. 
During the investigation of the state of the drug after spray drying, the multifunctional 
formulation has displayed an amorphous state without any indication for crystallization.




In this thesis, an innovative multifunctional formulation as a dry powder for inhalation 
composed out of multi-drug (antibiotics, NAC, Curcumin) was developed for the purpose of 
treating the bacterial infections of cystic fibrosis. The multifunctional formulation is a 
milestone for future treatment in cystic fibrosis, taking the benefit from the presence of the 
NAC to break the mucus network and facilitate the diffusion of the antibiotics and anti-
inflammatory drugs through the mucus. 
 
The next milestone of following this approach could be embedding this multifunctional 
microparticle matrix containing (NAC/antibiotics) with another kind of NPs with a different 
drug which might be a drug for genetic correction such as Ivacaftor. Moreover, this 
approach could be used with another kind of antibiotics to test whether there is a possibility 
to formulate it in salt form. One other option is to use this multifunctional matrix 
(NAC/antibiotics) to incorporate it into a hydrophilic carrier system such as gelatin NPs.  
 
Finally, in vivo data would be needed to give more validation about the benefit of the 
combination of multiple drugs in one formulation.  
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